Unchanged

Summary of findings {#CD012713-sec1-0001}
===================

Summary of findings for the main comparisonRibavirin versus no ribavirin for Crimean Congo haemorrhagic fever**Ribavirin compared to no ribavirin for Crimean Congo haemorrhagic feverPatient or population:** people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever **Setting:** global **Intervention:** ribavirin **Comparison:** no ribavirin**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)CommentsRisk with no ribavirinRisk with ribavirin**Mortality56 per 100063 per 1000 (16 to 240)RR 1.13 (0.29 to 4.32)136 (1 RCT)^1^⊕⊝⊝⊝ VERY LOW^2,3^‐Length of hospital stay (days)The mean length of hospital stay in 1 RCT was 0.7 days longer in the experimental group (0.39 days fewer to 1.79 days longer)‐136 (1 RCT)^4^⊕⊝⊝⊝ VERY LOW^2,3^‐Requirement for transfusion (platelets)306 per 1000376 per 1000 (235 to 599)RR 1.23 (0.77 to 1.96)136 (1 RCT)⊕⊝⊝⊝ VERY LOW^2,3^‐\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: CI:** confidence interval; **RCT**: randomised controlled trial; **RR:** risk ratio**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.[^2]

Summary of findings 2Early versus late supportive care plus ribavirin for Crimean Congo haemorrhagic fever**Early versus late supportive care plus ribavirin for Crimean Congo haemorrhagic feverPatient or population:** people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever **Setting:** global **Intervention:** early supportive care plus ribavirin^1^ **Comparison:** late supportive care plus ribavirin**OutcomesAnticipated absolute effects^\*^ (95% CI)Relative effect (95% CI)Number of participants (studies)Certainty of the evidence (GRADE)CommentsRisk with Late ribavirinRisk with Early ribavirin**Mortality in early versus late supportive care plus ribavirin400 per 1000156 per 1000 (64 to 380)RR 0.39 (0.16 to 0.95)63 (1 non‐randomised study)⊕⊝⊝⊝ VERY LOW^2,3^‐\***The risk in the intervention group** (and its 95% CI) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **Abbreviations: CI:** confidence interval; **RR:** risk ratio**GRADE Working Group grades of evidence** **High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect. **Moderate certainty:** we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. **Low certainty:** our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. **Very low certainty:** we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect.[^3]

Background {#CD012713-sec1-0002}
==========

Description of the condition {#CD012713-sec2-0001}
----------------------------

Crimean Congo haemorrhagic fever (CCHF) is a tick‐borne viral disease. The virus that causes CCHF is a Nairovirus, a member of the Bunyaviridiae family. The most common vectors of the disease are *Hyalomma* ticks, which spread the disease and also act as a disease reservoir. CCHF is found in Africa, Eastern Europe, the Middle East, and Asia, with further occasional cases in other European countries such as Spain and Greece ([@CD012713-bbs2-0131]; [@CD012713-bbs2-0153]; [@CD012713-bbs2-0128]). In recent years, CCHF incidence has been increasing in several areas worldwide ([@CD012713-bbs2-0153]).

The disease starts with a headache, fever, abdominal pain, musculoskeletal pain, and nausea. Over the next few days this is followed by gastro‐intestinal symptoms, including vomiting, diarrhoea, and haemorrhagic rash. After three to five days, a few patients progress to severe microvascular instability and the haemorrhagic phase of the illness, which is usually manifested first by a petechial rash followed by ecchymosis and bleeding. As the disease progresses into the second week, bleeding can worsen and become more severe, resulting most commonly in haemorrhage under the skin and within the abdomen. Death rates in people infected can reach up to 50% ([@CD012713-bbs2-0131]). In endemic areas where high‐quality supportive care and access to diagnostics are offered, death rates can be as low as 5% ([@CD012713-bbs2-0132]).

Many infections occur without symptoms and some estimates suggest this occurs in most infections ([@CD012713-bbs2-0116]). CCHF severity varies in people who are clinically unwell. Different scores to assess severity are used but it remains unclear what proportion of all infections are severe ([@CD012713-bbs2-0147]; [@CD012713-bbs2-0005]).

Infection in people is usually due to a tick bite or by contact with infected bodily fluids from humans or animals ([@CD012713-bbs2-0124]). Those at highest risk of contracting the virus are people who work outdoors in CCHF‐endemic areas, those who work with large domestic animals, and healthcare workers (Whitehouse 2004). CCHF has been linked to reservoirs such as sheep, goats, hedgehogs, and hares ([@CD012713-bbs2-0118]; [@CD012713-bbs2-0142]; [@CD012713-bbs2-0152]; [@CD012713-bbs2-0143]). Human‐to‐human transmission occurs within families and in healthcare settings, including nosocomial outbreaks. The greatest risk of nosocomial exposure is from splash exposures and needle stick injuries (Conger 2015; [@CD012713-bbs2-0060]). Case series studies also suggest that in rare cases airborne transmission from ventilated patients may also occur ([@CD012713-bbs2-0078]). Case reports suggest possible sexual transmission, although there is no published evidence of the virus being present in seminal or vaginal fluid ([@CD012713-bbs2-0140]). The virus is also transmitted from person to person by infected bodily fluids, and is highly infectious.

The disease may become more important in future years because of changes to the habitat of the *Hyalomma* tick vector, which is due in part to changes in the rural landscape from large diffuse habitats to smaller habitats. This is shown to lead to densely‐populated habitats for the tick vector, which is associated with increasing incidence of the disease ([@CD012713-bbs2-0125]). Given the high mortality of patients, the lack of a widely‐available viable vaccine ([@CD012713-bbs2-0122]), and an emerging pattern of spread with multiple countries reporting re‐emergence of epidemics or new cases ([@CD012713-bbs2-0134]), CCHF should be considered a potential threat to public health.

Description of the intervention {#CD012713-sec2-0002}
-------------------------------

Supportive medical care underpins CCHF treatment, and use of fluids, good nursing care, and blood products in response to changes in the blood\'s ability to clot are key components ([@CD012713-bbs2-0133]). Previous attempts at therapeutic regimens have explored intravenous (IV) immunoglobulin (Ig) isolated from horses ([@CD012713-bbs2-0131]), and from recovered patients ([@CD012713-bbs2-0148]), but these are not currently widely used.

Ribavirin is commonly used with interferon to treat people who have hepatitis C, and is used alone in treating people who have Lassa fever ([@CD012713-bbs2-0120]). Ribavirin is also used in healthcare settings as a form of post‐exposure prophylaxis for those exposed to CCHF ([@CD012713-bbs2-0060]). Non‐randomized studies show that it could be effective in treating cases of CCHF ([@CD012713-bbs2-0127]; [@CD012713-bbs2-0015]; [@CD012713-bbs2-0005]), although this has been debated ([@CD012713-bbs2-0013]; [@CD012713-bbs2-0060]). One such idea is that administration of ribavirin early in the disease, when it appears to be at its most effective, may be a promising approach ([@CD012713-bbs2-0005]; [@CD012713-bbs2-0073]). This fits with the known course of the disease, where the virus is most commonly only present in the blood within the first week following onset of CCHF symptoms ([@CD012713-bbs2-0115]).

Ribavirin has adverse effects, and, as well as the questions about its efficacy, clinicians debate whether or not to risk using the drug ([@CD012713-bbs2-0119]; [@CD012713-bbs2-0139]). Some of the adverse effects include risks of haemolysis, arrhythmia, bone marrow suppression, and deranged liver function ([@CD012713-bbs2-0123]). Two previous systematic reviews have shown no clear benefit of ribavirin in people with CCHF, although the available evidence is limited mainly to confounded non‐randomized data ([@CD012713-bbs2-0145]; [@CD012713-bbs2-0114]).

No alternative therapy has been proposed as the mainstay of therapeutic treatment. Although newer drugs, such as favipiravir, have shown promise in vitro ([@CD012713-bbs2-0138]), widespread adoption of new therapies is years away. Current treatment guidelines and case definitions vary from region to region and from country to country ([@CD012713-bbs2-0121]; [@CD012713-bbs2-0013]).

How the intervention might work {#CD012713-sec2-0003}
-------------------------------

Ribavirin is a synthetic nucleoside that is active against a broad spectrum of DNA and RNA viruses ([@CD012713-bbs2-0144]). It is one of few drugs shown to be active against CCHF in vitro ([@CD012713-bbs2-0149]). Ribavirin can be given in hospital settings either intravenously or orally, according to World Health Organization (WHO) recommendations ([@CD012713-bbs2-0150]). National guidelines from countries such as South Africa ([@CD012713-bbs2-0121]), India ([@CD012713-bbs2-0136]), and Pakistan ([@CD012713-bbs2-0137]) recommend prompt treatment with ribavirin following diagnosis of CCHF. However, these recommendations for management are not based on a robust evidence base ([@CD012713-bbs2-0145]). CCHF can be mild or more severe, and it is often not deemed necessary to treat mild cases of the disease ([@CD012713-bbs2-0007]). Questions remain about the overall benefits of ribavirin, how long after the onset of symptoms it is most effective, and whether it is more or less effective in severe cases ([@CD012713-bbs2-0124]; [@CD012713-bbs2-0005]; [@CD012713-bbs2-0132]).

Why it is important to do this review {#CD012713-sec2-0004}
-------------------------------------

The controversy surrounding ribavirin use and the benefits of a widely‐available treatment for CCHF mean an up‐to‐date review of the existing evidence is required. There are mixed views on whether to treat CCHF with ribavirin, given the uncertainty about the balance between potential but unproven benefit and known risks of the drug ([@CD012713-bbs2-0013]). It is therefore important to use the data available to address whether ribavirin reduces the number of deaths from a lethal disease, whilst assessing the possibility of harm from serious, life‐threatening adverse effects.

Objectives {#CD012713-sec1-0003}
==========

To assess the effects of ribavirin for treating people with Crimean Congo haemorrhagic fever (CCHF).

Methods {#CD012713-sec1-0004}
=======

Criteria for considering studies for this review {#CD012713-sec2-0005}
------------------------------------------------

### Types of studies {#CD012713-sec3-0001}

We included the following types of study:

Randomized controlled trials (RCTs), quasi‐RCTs, and non‐randomized controlled studies of ribavirin compared to no ribavirin; also studies comparing early versus late administration of ribavirinCohort studies with ribavirin compared to no ribavirin, and studies comparing early versus late administration of ribavirin (prospective and retrospective, with more than 10 participants).Case‐control studies with ribavirin compared to no ribavirin, and studies comparing early versus late administration of ribavirin

### Types of participants {#CD012713-sec3-0002}

Children or adults of any age with CCHF confirmed with a laboratory test (immunoglobulin (Ig) or polymerase chain reaction (PCR))

### Types of interventions {#CD012713-sec3-0003}

#### Intervention {#CD012713-sec4-0001}

Ribavirin (intravenous (IV) or oral)Early ribavirin (as defined in identified studies)

#### Control {#CD012713-sec4-0002}

Supportive care onlyLate ribavirin (as defined by study authors)

We accepted co‐interventions as long as the indication for the co‐intervention was consistent between groups, for example, administration of platelets according to homeostatic need.

### Types of outcome measures {#CD012713-sec3-0004}

#### Primary outcomes {#CD012713-sec4-0003}

Death (in hospital or 28 days post‐admission)

#### Secondary outcomes {#CD012713-sec4-0004}

Length of hospital stay (days)Requirement for transfusion (any blood products, including platelets, fresh frozen plasma, packed red cells, or whole blood)Withdrawal of treatment due to serious adverse eventsSerious adverse events, as defined according to the accepted US Food and Drug Administration (FDA) definition of: \"if in the view of the investigator or sponsor, the event results in any of the following outcomes: death, life threatening adverse event, inpatient hospitalizations, prolongation of existing hospitalisation, disability or permanent damage, congenital abnormality, required intervention to prevent permanent impairment or other serious medical events\" ([@CD012713-bbs2-0126]).

Search methods for identification of studies {#CD012713-sec2-0006}
--------------------------------------------

We tried to identify all relevant trials, regardless of language or publication status (published, unpublished, in press, and in progress).

### Electronic searches {#CD012713-sec3-0005}

We searched the following databases using the search terms and strategy described in [Appendix 1](#CD012713-sec2-0015){ref-type="app"}: the Cochrane Infectious Diseases Group Specialized Register (16 October 2017); the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 9 of 12, September 2017), published in the Cochrane Library; MEDLINE (PubMed, 1966 to 16 October 2017); Embase (OVID, 1947 to 16 October 2017); Science Citation Index‐Expanded, Social Sciences Citation index, conference proceedings (Web of Science, 1900 to 16 October 2017); and CINAHL (EBSCOHost (1982 to 16 October 2017). We also searched the WHO International Clinical Trials Registry Platform (ICTRP; [www.who.int/ictrp/en/](www.who.int/ictrp/en/)) and ClinicalTrials.gov ([clinicaltrials.gov/ct2/home](clinicaltrials.gov/ct2/home)) for trials in progress, up to 16 October 2017, using \"ribavirin\" and \"Crimean Congo haemorrhagic fever\" or \"CCHF\" as search terms.

### Searching other resources {#CD012713-sec3-0006}

We searched the reference lists of any relevant systematic reviews. We contacted researchers in the field, requested information about grey literature and ongoing studies from the WHO, and checked reference lists of included studies.

Data collection and analysis {#CD012713-sec2-0007}
----------------------------

### Selection of studies {#CD012713-sec3-0007}

Two review authors independently screened all citations and abstracts identified in the search according to predefined inclusion criteria. We obtained the full‐text reports of all potentially eligible studies or studies we were unclear about. Two review authors independently screened these full‐text articles, resolving any disagreements through discussion and if necessary consulting a third review author. We listed all studies excluded after full‐text assessment and their reasons for exclusion in the '[Characteristics of excluded studies](#CD012713-sec2-0021){ref-type="sec"}\' table.

We included all unique studies in analyses; however, if there were any studies at critical risk of bias we excluded them from the main effects analyses. We included studies at critical risk of bias in a subsidiary descriptive analysis, using non‐overlapping samples as described in [Appendix 2](#CD012713-sec2-0016){ref-type="app"}.

### Data extraction and management {#CD012713-sec3-0008}

One review author extracted data using pre tested data extraction forms. A second review author cross‐checked the extracted data. We resolved any disagreements about data extraction by referring to the study report and through discussion. We attempted to contact the study authors where data were insufficient or missing.

We extracted data using a tool tailored for the inclusion criteria described above, including the following information:

Dose and method of administration (oral or IV)Adult or child populationsLocationSettingDesignStudy sizeDatesDeathLength of hospital stay (days)Transfusion of blood productsSerious adverse eventsTime since onset of symptoms (days) to treatment with ribavirin or supportive care only

### Assessment of risk of bias in included studies {#CD012713-sec3-0009}

Two review authors assessed the risks of bias of each included study, resolving any disagreements through discussion and consulting a third review author if necessary. For RCTs or quasi‐RCTs, we used the Cochrane 'Risk of bias\' tool for RCTs ([@CD012713-bbs2-0130]). For non‐randomized studies, we used the ROBINS‐I tool (Risk Of Bias In Non‐randomized Studies ‐ of Interventions) ([@CD012713-bbs2-0146]).

We assessed risks of bias through a hierarchy of domains, starting with critical then serious, moderate, and low. If any domain reached critical risk of bias we did not continue with the assessment, as further evaluation would not influence how we assess the certainty of the evidence.

As the risk of bias in the effect of an intervention may be different for different outcomes, we made a 'Risk of bias\' assessment for each outcome.

Our full methods for using ROBINS‐I are set out in [Appendix 3](#CD012713-sec2-0017){ref-type="app"}. For assessment of confounding we considered length of time from onset of symptoms to receiving medical care or ribavirin, severity of disease, historical controls rather than contemporary controls, and quality of supportive care to be confounding domains. We made the decision to define these as confounding factors based on extensive debate in the literature ([@CD012713-bbs2-0042]; [@CD012713-bbs2-0145]; [@CD012713-bbs2-0013]), alongside consultation with clinicians with experience of treating viral haemorrhagic fever and CCHF. We listed co‐interventions that could differ between intervention groups impacting on outcomes as 'quality of supportive care\'.

The ROBINS‐I tool recommends only including non‐randomized studies that are not classified as having critical risk of bias. For our main effects analysis, we followed this approach. In addition, there was a further set of studies which met the inclusion criteria but which we classified as having critical risk of bias. As some of these studies have traditionally been used as part of the evidence base, we carried out a subsidiary descriptive analysis describing these studies and their estimates of effect. We established a non‐overlapping sample and performed meta‐analysis to describe the effect of confounding.

### Measures of treatment effect {#CD012713-sec3-0010}

We analysed data using Review Manager 5 (RevMan 5) ([@CD012713-bbs2-0141]). For dichotomous outcomes, we presented analyses using risk ratios (RRs) with their 95% confidence intervals (CIs). For continuous data we used mean differences (MDs) with their 95% CIs.

### Unit of analysis issues {#CD012713-sec3-0011}

We did not identify any studies that used a cluster‐randomized design or multiple interventions. For our subsidiary descriptive analysis of studies at critical risk of bias we established a non‐overlapping sample of studies using decision rules and methods set out in [Appendix 2](#CD012713-sec2-0016){ref-type="app"}.

If we had identified studies of a cluster design we would have only used adjusted measures of effect. If the included study had not performed any adjustment for clustering, we would have adjusted the raw data ourselves, using an intracluster correlation coefficient (ICC).

We did not identify any studies with multiple intervention arms, but if we had we would have included data from these studies by either combining treatment arms, or by splitting the control group so that we only include participants once in the meta‐analysis.

### Dealing with missing data {#CD012713-sec3-0012}

We attempted to contact the study authors to obtain missing data when the lack of reporting of necessary data restricted the use of the study.

We applied no imputation measures for missing data.

In one study there was an unclear amount of missing data from an analysis looking at the added benefit of corticosteroid use as well as ribavirin ([@CD012713-bbs2-0005]). This occurred because the number of participants included in the analysis did not tally with the explanation of how data were analysed in the text. These missing data may have affected the adjusted odds ratio (OR) presented in the study. We took this into account in the 'Risk of bias\' assessment, and it affected our decision not to present the adjusted estimate of effect; instead we presented a forest plot with the results stratified by severity of diease. As the missing data did not affect results relating to ribavirin and mortality, we did not classify the study as being at critical risk of bias.

### Assessment of heterogeneity {#CD012713-sec3-0013}

We examined the included studies to determine whether there was heterogeneity in terms of co‐intervention, level of supportive care available, and risks of bias in the included studies.

We inspected forest plots to assess whether statistical heterogeneity was present. We deemed CIs that did not overlap as an indication of statistical heterogeneity. We also performed the Chi^2^ test using a cut‐off point of P \< 0.10 to indicate statistical heterogeneity, and we used the I^2^ statistic to quantify the heterogeneity. We interpreted the I^2^ statistic value according to guidance in the *Cochrane Handbook of Systematic Reviews of Intervention*s ([@CD012713-bbs2-0130]).

### Assessment of reporting biases {#CD012713-sec3-0014}

If applicable, we intended to use funnel plot analysis or statistical tests (such as the Egger regression test), or both, to assess for publication bias. We planned to perform funnel plot analysis if there were more than 10 studies in any meta‐analysis. As there were fewer than 10 studies included in any of the effects analyses we did not perform this test.

### Data synthesis {#CD012713-sec3-0015}

In order to deal with non‐standard study designs we have presented our main effects analysis by study design. We separated study designs into different subgroups and did not pool results across randomised and non‐randomized subgroups. This included RCTs, retrospective cohort studies, matched cohort studies and historically‐controlled cohort studies.

We stratified studies by their risk of bias in the descriptive analysis. We did not include studies which we assessed as having critical risk of bias in the main effects analysis. We performed a meta‐analysis of studies using the random‐effects model; this was due to varying study type, differences in populations and supportive therapy available.

We examined those studies classified as being at critical risk of bias in a subsidiary descriptive analysis that assessed the degree of confounding. We assembled a non‐overlapping sample, as set out in [Appendix 2](#CD012713-sec2-0016){ref-type="app"}.

One study ([@CD012713-bbs2-0005]) used a model to adjust for confounding of effect due to severity of disease. This resulted in an adjusted OR of 0.04 (95% CI 0.004 to 0.48). The small sample size, the size of the adjusted effect, missing data from the corticosteroid analysis, concerns about residual confounding due to time from onset of symptoms to presentation to hospital/administration of ribavirin, and the fact that the study analysed severely‐ill patients with gastro‐intestinal haemorrhage \"per protocol\" and not by intention‐to‐treat, meant that we took a conservative approach to synthesis. We presented non‐adjusted data from the study in the main effects analysis, and the stratified data in a separate analysis ([Analysis 1.2](#CD012713-fig-00102){ref-type="fig"}).

We used the GRADE approach to assess the certainty of the evidence, and created 'Summary of findings\' tables and Evidence Profiles ([@CD012713-bbs2-0129]). Data from observational studies started as low quality, but we intended to upgrade this to moderate or high quality if the pooled estimates revealed a large effect size, negligible concerns about confounders, or a strong dose‐response gradient.

### Subgroup analysis and investigation of heterogeneity {#CD012713-sec3-0016}

If unexplained heterogeneity occurred we intended to perform subgroup analyses of the results, to assess whether the effect of ribavirin was influenced by any of the following factors:

Severity of symptoms: severe, moderate, mildDuration of treatment, presence of severe gastro‐intestinal symptoms, and route of administrationAge (children versus adults). Children are defined as under 16 years of age.

We did not conduct subgroup analyses, because there were insufficient data to apply the prespecified subgroups in the primary effects analysis.

### Sensitivity analysis {#CD012713-sec3-0017}

If we had estimated an ICC to adjust the results from cluster trials, we would have performed sensitivity analyses to investigate the robustness of our findings. We had intended to perform a sensitivity analysis, to consider excluding studies that were at high risk of bias according to the Cochrane 'Risk of bias\' tool for RCTs ([@CD012713-bbs2-0130]), and serious risk of bias according to ROBINS‐I tool for observational studies ([@CD012713-bbs2-0146]).

We performed no sensitivity analyses because we identified no cluster‐controlled studies, and because all studies included in the main effects analysis were at high risk of bias according to the Cochrane tool or at serious risk of bias according to ROBINS‐I.

Results {#CD012713-sec1-0005}
=======

Description of studies {#CD012713-sec2-0008}
----------------------

### Results of the search {#CD012713-sec3-0018}

See PRISMA flow diagram [Figure 1](#CD012713-fig-0001){ref-type="fig"}.Figure 1Flow of studies

We identified 1161 records, plus a further three references through contacting experts in the field. From these we identified 611 unique references after removing duplicates. We considered 372 references to be irrelevant for our review, and we were unable to obtain the articles for 13 of the references. We considered 226 full‐text articles for inclusion, of which we excluded 203. Two did not report on CCHF, and two reported on outcomes not included in our review. Fifty‐one studies did not report on ribavirin for treating CCHF, nine had no comparator arm and 27 were single‐case reports. Fifty were cohort studies with fewer than 10 participants, 27 were narrative reviews and 35 studies were editorial letters or comments on other studies. Twenty‐three studies met our inclusion criteria and are included in the review. No prospectively‐registered ongoing studies met the inclusion criteria.

### Included studies {#CD012713-sec3-0019}

See [Characteristics of included studies](#CD012713-sec2-0020){ref-type="sec"}.

We include 23 studies that tested the use of ribavirin in people with CCHF, with the outcomes of mortality, length of hospital stay, and requirement for transfusion.

#### Main effects analysis {#CD012713-sec4-0005}

For the main effects analysis we include five studies that were not at critical risk of bias; one RCT of 136 participants ([@CD012713-bbs2-0014]) and four non‐randomized studies of 612 participants ([@CD012713-bbs2-0006]; [@CD012713-bbs2-0012]; [@CD012713-bbs2-0003]; [@CD012713-bbs2-0005]).

##### Study design {#CD012713-sec5-0001}

Of the five studies included in our main effects analysis, one study was an RCT ([@CD012713-bbs2-0014]), one was a matched cohort study ([@CD012713-bbs2-0003]), one was a cohort with a historical control ([@CD012713-bbs2-0006]), one was a mixed prospective and retrospective cohort study ([@CD012713-bbs2-0005]), and one was a retrospective cohort ([@CD012713-bbs2-0012]).

The design of the studies included in our primary analysis and how controls were selected varied. [@CD012713-bbs2-0006] used historical controls from a period when ribavirin was unavailable. [@CD012713-bbs2-0005] selected controls based on clinical criteria including time from onset of symptoms to diagnosis or contraindication to oral ribavirin. [@CD012713-bbs2-0012] compared administration of ribavirin given early in the disease to late in the disease. [@CD012713-bbs2-0003] used a retrospective design that matched 10 participants who received ribavirin to 40 controls that did not, using various clinical and physiological parameters.

##### Setting {#CD012713-sec5-0002}

Four out of the five studies included in the main effects analysis were conducted in Turkey, and one was conducted in Iran ([@CD012713-bbs2-0012]).

##### Participants {#CD012713-sec5-0003}

Most participants described in [@CD012713-bbs2-0005] were adults or adolescents, with the youngest participant aged 16 years. [@CD012713-bbs2-0012] described an age range of 11 to 75, with a median age of 29.2 years. It was not possible to ascertain the exact numbers of adolescents, as they were not described in the included studies. All of the studies included in our main effects analysis included confirmed cases only, using either Ig enzyme‐linked immunosorbent assay (ELISA) or PCR to verify.

##### Intervention {#CD012713-sec5-0004}

Doses of ribavirin differed between studies. [@CD012713-bbs2-0006] described weight‐based prescribing (30 mg/kg initial loading dose; 15 mg/kg 4 times daily for 4 days; 7.5 mg/kg 3 times daily for 6 days). [@CD012713-bbs2-0005] and [@CD012713-bbs2-0003] described standard doses in adults (4 g daily for 4 days, followed by 2.4 g daily for 6 days). Doses were broadly the same and full details are described in the '[Characteristics of included studies](#CD012713-sec2-0020){ref-type="sec"}\' table. All studies in this analysis administered oral ribavirin.

##### Comparators {#CD012713-sec5-0005}

None of the participants in the comparator groups received ribavirin for the comparison of ribavirin versus no ribavirin. One study ([@CD012713-bbs2-0012]) was included in the main effects analysis that offered a comparison of early versus late ribavirin; all those in the comparator arm received ribavirin after four days.

##### Length of follow‐up {#CD012713-sec5-0006}

No studies specified a length of follow‐up. Instead, they relied upon discharge from hospital or clinical care as the sole measure of follow‐up time.

#### Subsidiary descriptive analysis {#CD012713-sec4-0006}

For the subsidiary descriptive analysis we included 18 studies rated at critical risk of bias. These studies are frequently cited as evidence of benefit, so we appraised them against the primary outcome of mortality.

##### Study design {#CD012713-sec5-0007}

The rationale for 'Risk of bias\' assessments is set out in [Table 7](#CD012713-tbl-0007){ref-type="table"}. They all failed to control for confounding due to severity of disease, time from the onset of symptoms to receiving medical care, or all of these. This critically affected the reliability of data collected for these studies. ROBINS‐I recommends studies at critical risk of bias are excluded from the review.Table 1Table of studies at critical risk of bias: disease‐related outcomes**Studies at critical risk of bias outcomes: Death, timing of administration, length of stay in hospital, requirement for transfusionStudyBias due to ConfoundingComment**[@CD012713-bbs2-0001]CriticalConfounders not controlled for. No information reported on care received in hospital. Variation in disease severity between ribavirin and control groups not measured. No discussion of potential confounding by severity of disease in paper. No control for time from onset of symptoms to administration of ribavirin. Small size of control group suggests clinical contraindication to ribavirin, a factor in selection into control group (although this is not expressly commented on)[@CD012713-bbs2-0002]CriticalConfounders not controlled for. Although criteria for administration of ribavirin reported, it is not clear whether recipients must fulfil all of these or only some\
Participants receiving ribavirin were more severe at baseline. There is no adjustment for severity on admission, and length of time between symptom onset and admission/ribavirin treatment[@CD012713-bbs2-0004]CriticalConfounders not controlled for. Severe patients only included in case‐control study. No discussion of potential confounding in paper. Care provided during hospitalisation not described[@CD012713-bbs2-0007]CriticalConfounders not controlled for. Severe patients only included in retrospective cohort. Baseline severity of disease not established. Classification of severe disease is at any time point for 22 participants. Time from onset of symptoms not controlled for. No method for dealing with potential confounders. Patients were given preparations of erythrocytes, fresh frozen plasma, and total blood, depending on their homeostatic state ‐ disentangling the effect of this supportive care from that of ribavirin is not considered. Oral ribavirin was given to severe CCHF patients[@CD012713-bbs2-0008]CriticalConfounders not controlled for. Paper focuses on developing severity scoring system. Baseline characteristics not established between ribavirin and non‐ribavirin groups. Criteria for selection into control arm included clinical contraindication due to haematemesis. Time from onset of symptoms not controlled for. The authors developed specific criteria to identify severe cases[@CD012713-bbs2-0010]CriticalConfounders not controlled for. No methods for controlling potential confounders are discussed. Authors stated in Discussion that no information was available to them on severity of cases. No information reported on care received by participants[@CD012713-bbs2-0009]CriticalConfounders not controlled for. Controls for "time from onset of symptoms" for a comparison of early versus late ribavirin. However, not for the comparison of ribavirin versus no ribavirin. Rather than just comparing means, the authors should control for the confounders when comparing the groups. Mortality not reported[@CD012713-bbs2-0011]CriticalConfounders not controlled for. Paper focuses on bradycardia in paediatric patients\
No discussion of potential confounding in paper and no controlling for confounding factors such as severity of illness or time from onset of symptoms to administration of ribavirin[@CD012713-bbs2-0013]CriticalConfounders not controlled for. Significant differences in baseline severity of disease and time from onset of symptoms. These confounders were measured but not controlled for by stratification or other method. Ribavirin group had more severe disease; confounding would reduce effect of ribavirin seen[@CD012713-bbs2-0015]CriticalConfounders not controlled for. Baseline characteristics not established between ribavirin and no‐ribavirin groups. No method for dealing with potential confounders. Significant differences in arms of study ‐ suggests heterogeneous samples with no controlling for severity of disease. Time from disease onset to presentation/treatment not assessed. Historical control arm used supportive treatment likely to have differed substantially between intervention and control arms[@CD012713-bbs2-0016]CriticalConfounders not controlled for. Conference abstract ‐ insufficient information reported by study authors about possible confounders such as severity of disease. No information provided on care received in hospital[@CD012713-bbs2-0017]CriticalConfounders not controlled for. No methods for controlling potential confounders are discussed. Timing of administration of ribavirin is documented but severity of infection is not considered. Baseline characteristics not established between ribavirin and no‐ribavirin groups[@CD012713-bbs2-0018]CriticalHistorical control group used. Study conducted from 1999‐2008, quality of supportive care likely to have changed significantly over this period of time. Control group originated during period before ribavirin was available. Substantial period of time from the start of follow up in historical control group to start of follow up in intervention group.[@CD012713-bbs2-0019]CriticalConfounders not controlled for. No information reported on care received in hospital. Baseline characteristics not established. Variation in disease severity expected, although influence of this across the two groups unclear. No method of controlling for confounding by severity of disease. No discussion of potential confounding in paper. Timing of administration investigated, raw data not presented.[@CD012713-bbs2-0020]CriticalConfounders not controlled for. Time from onset of symptoms adjusted for by stratification into early/late ribavirin. Baseline characteristics and severity of disease not assessed, measured or controlled for. No information provided on care received in hospital[@CD012713-bbs2-0021]CriticalTiming of administration of ribavirin controlled for by stratification. Baseline confounding due to severity of disease measured and not controlled for participants in no‐ribavirin group and late‐ribavirin group having more severe disease based on baseline biochemistry and haematology. At least one participant was included in no‐ribavirin group due to gastrointestinal haemorrhage and severe disease. Criteria for use of ribavirin changed during period and largely historical controls were used[@CD012713-bbs2-0022]CriticalConfounders not controlled for. No methods for controlling potential confounders such as severity of disease and time since onset of symptoms are discussed. Authors recognize highly‐confounded data as limitation of their study[@CD012713-bbs2-0023]CriticalConfounders not controlled for. Case‐control study with no information in abstract about how the controls were selected. Supportive care protocol was similar in both departments. No method for dealing with potential confounding by time since onset of symptoms. No matching for severity or time since onset of symptoms[@CD012713-bbs2-0024]CriticalConfounders not controlled for. No method for dealing with potential confounding by time since onset of symptoms, baseline characteristics were not established, no method for controlling for severity. The patients were given erythrocyte suspension, thrombocyte suspension and/or fresh frozen plasma based on their haemostasis status, and other supportive care when necessary ‐ disentangling the effect of this care from that of ribavirin is not considered. Oral ribavirin was given to the patients who were evaluated as severe or had bleeding symptoms, or both.\
Entirely unclear how the authors selected the 50 participants included from 202 confirmed cases. Also at critical risk of bias on selection of participants into the study

All 18 studies at critical risk of bias were retrospective cohort studies. One study used a cohort of patients treated before the availability of ribavirin as a control arm. ([@CD012713-bbs2-0018]).

##### Setting {#CD012713-sec5-0008}

In those studies included in the descriptive analysis 12 were conducted in Turkey, five were conducted in Iran and one study was set in Russia and was translated from Russian ([@CD012713-bbs2-0018]). There were a number of studies that reported on populations that overlapped with each other. Our decisions on overlapping studies are outlined in [Appendix 2](#CD012713-sec2-0016){ref-type="app"}.

##### Participants {#CD012713-sec5-0009}

In the subsidiary descriptive analysis for the comparison of ribavirin versus no ribavirin an additional 1214 participants in 10 studies at critical risk of bias were analysed.

In the subsidiary descriptive analysis for the comparison of early versus late ribavirin an additional 431 participants in 4 studies received either early or late ribavirin.

##### Intervention {#CD012713-sec5-0010}

For the comparison of ribavirin versus no ribavirin doses were broadly the same; we give full details in the '[Characteristics of included studies](#CD012713-sec2-0020){ref-type="sec"}\' table. Most studies in this analysis administered oral ribavirin.

For the comparison of early versus late ribavirin, participants received ribavirin according to the study author\'s definitions of early versus late. Studies used different cut‐off time points for the definition of early care with ribavirin, either less than three days since onset of symptoms ([@CD012713-bbs2-0019]; [@CD012713-bbs2-0020]), less than four days since onset of symptoms ([@CD012713-bbs2-0012]) or less than five days since the onset of symptoms ([@CD012713-bbs2-0016]; [@CD012713-bbs2-0021]). 114 participants received ribavirin less than three days from the onset of symptoms, 97 received ribavirin after 3 days since the onset of symptoms. One hundred and thirty participants received ribavirin less than five days from onset of symptoms with 90 participants receiving ribavirin after this time point.

##### Comparators {#CD012713-sec5-0011}

Of those studies covered by the descriptive analysis, four studies included children only ([@CD012713-bbs2-0019]; [@CD012713-bbs2-0024]; [@CD012713-bbs2-0011]; [@CD012713-bbs2-0022]). Three studies did not report the method used to confirm cases of CCHF ([@CD012713-bbs2-0016]; [@CD012713-bbs2-0023]; [@CD012713-bbs2-0020]), all other studies used either Ig ELISA or PCR.

##### Length of follow‐up {#CD012713-sec5-0012}

No studies specified a length of follow‐up. Instead they relied upon discharge from hospital or clinical care as the sole measure of follow‐up time.

### Excluded studies {#CD012713-sec3-0020}

We excluded 203 studies at the full‐text screening stage because they did not study CCHF, did not relate to a relevant CCHF topic, had fewer than 10 participants, or they were narrative reviews or commentaries. See the [Excluded studies](#CD012713-sec3-0020){ref-type="sec"} tables.

Risk of bias in included studies {#CD012713-sec2-0009}
--------------------------------

### Main effects analysis {#CD012713-sec3-0021}

#### Randomized controlled trials {#CD012713-sec4-0007}

We identified one randomised control trial ([@CD012713-bbs2-0014]), which we assessed using the Cochrane 'Risk of bias\' tool for RCTs ([@CD012713-bbs2-0130]). Methods for random sequence generation and allocation concealment were unclear in the single RCT. The trial authors did not report methods for this in the text. We judged the methods for blinding of participants and outcome assessments to be unclear; we identified no missing data.

There was no protocol available to assess selective reporting. We judged mortality and length of hospital stay as unlikely to be subject to reporting bias ([Figure 2](#CD012713-fig-0002){ref-type="fig"}).Figure 2'Risk of bias\' assessment for all included trials

#### Non‐randomized studies {#CD012713-sec4-0008}

We identified 22 non‐randomized studies, which we assessed using the ROBINS‐I tool. Of these we classified 18 studies as being at critical risk of bias, and four studies at serious risk of bias.

##### Confounding {#CD012713-sec5-0013}

We have presented comprehensive 'Risk of bias\' assessments for non‐randomized studies included in the main effects analysis in [Table 8](#CD012713-tbl-0008){ref-type="table"}; [Table 9](#CD012713-tbl-0009){ref-type="table"}; [Table 10](#CD012713-tbl-0010){ref-type="table"}; [Table 11](#CD012713-tbl-0011){ref-type="table"}.Table 2ROBINS‐I assessment: Bodur 2011**ROBINS‐I assessmentReference**: [@CD012713-bbs2-0003]**Risk of bias domainAssessments by outcomeCommentConclusionBias due to confounding**Mortality, Length of hospital stay, transfusion, withdrawal of treatment: serious risk of bias due to baseline confoundingMatching controls were included in the study in order to increase the study\'s power. Baseline characteristics established and are similar between groups for severity of disease and time from onset of symptoms to admission.\
No significant differences in baseline laboratory findings. Differences occur between groups in rates of splenomegaly (1 case in each arm), petechiae, haematemesis (2/10 in ribavirin group, 3/40 in control), melena. However, limited information reported on how the controls or baseline characteristics were selected.Given the differences in clinical symptoms serious risk of bias was attributedSerious**Bias in selection of participants into the study**Mortality, length of hospital stay, transfusion, withdrawal of treatment: serious risk of bias.\
Direction: would show increased effect of ribavirinSelection into study did not appear to be related to intervention, outcome or any prognostic factor.\
Limited information reported on how the controls were selected.\
Controls selected "at random" that matched baseline characteristicsModerate**Bias in classification of interventions**All outcomesInterventions well definedLow**Bias due to deviations from intended interventions**All outcomesNo information on deviation from intended intervention, as would be the case in usual practiceLow**Bias due to missing data**All outcomes: seriousAll data appear to be reportedLow**Bias in selection of the reported result**All outcomesNo outcomes of interest to study authors are specified. No protocol available, no prespecified outcomes in Methods sectionSeriousTable 3ROBINS‐I assessment Dokuzoguz 2013**ROBINS‐I assessmentReference:**[@CD012713-bbs2-0005]**DomainAssessments by outcomeCommentConclusionBias due to confounding**Mortality, length of hospital stay, transfusion, withdrawal of treatment: Serious risk of bias due to baseline confoundingTime from onset of symptoms not adequately controlled or adjusted for. All participants with time from onset of symptoms to diagnosis \< 7 days received ribavirin unless contraindicated\
Both time from onset of symptoms and clinical contraindication are prognostic factors that predict whether the individual receives the interventionSerious**Bias in selection of participants into the study**Mortality, length of hospital stay, transfusion, withdrawal of treatment: serious risk of biasControl group selected by including patients with time from onset of symptoms to diagnosis \> 7 days and clinical contraindication to ribavirin\
Both time from onset of symptoms and clinical contraindication are prognostic factors that predict whether the individual receives the intervention\
Analysis was performed per protocol (2 participants in control group were intended to be treated with ribavirin but due to gastrointestinal bleeding were unable to receive oral medication)Serious**Bias in classification of interventions**All outcomesInterventions well‐defined in Methods sectionLow**Bias due to deviations from intended interventions**All outcomesNo deviation from intervention not expected in normal practiceLow**Bias due to missing data**All outcomesSome missing outcome data not dealt with in text. This is related to numbers of participants receiving co‐administration of corticosteroids with ribavirin Unbalanced across groupsSerious**Bias in selection of the reported result**All outcomesAnalysis was performed per protocol. (2 participants in control group were intended to be treated with ribavirin but due to gastrointestinal bleeding were unable to receive oral medication). Effect of ribavirin as measured will be overestimated compared to intention‐to‐treat analysisSeriousTable 4ROBINS‐I assessment: Elaldi 2009**ROBINS‐I assessmentReference**: [@CD012713-bbs2-0006]**Risk of bias domainAssessments by outcomeCommentConclusionBias due to confounding**Mortality, length of hospital stay, transfusion, withdrawal of treatment: Serious risk of bias due to baseline confoundingBaseline characteristics established and are similar between groups for severity of disease and time from onset of symptoms to admission\
Differences occur between groups in rates of maculopapular rash, hepatomegaly and lactate dehydrogenase. None of these are markers of disease severity unless petechiae were misclassified as maculopapular rash\
Use of historical control arm at the onset of an epidemic establishes a difference in the quality of supportive care between groups. As the time elapsed was only one year we classified this as serious and not critical confounding\
No participants diagnosed received ribavirin in the historical control group All participants diagnosed received ribavirin in the intervention group\
No method to adjust for potential confounders reportedSerious**Bias in selection of participants into the study**Mortality, length of hospital stay, transfusion, withdrawal of treatmentSelection into study was not related to intervention, outcome or any prognostic factor\
Historical control group may confound results as set out above\
It appears that all potential participants for the specified study years have been included in the studies for the particular treatment groupsSerious**Bias in classification of interventions**All outcomesInterventions well‐defined in Methods sectionLow**Bias due to deviations from intended interventions**All outcomesNo information reported on adherence of participants to ribavirin treatment schedule. For supportive care: \"Same proportions of patients received ES (12%) and FFP (39%) in treated and untreated groups. On the other hand, more patients in the treated group were infused with PS (52%) than those in the untreated group (42%).\" No other information provided about co‐interventionsLow**Bias due to missing data**All outcomes: seriousAll data appear to be reportedLow**Bias in selection of the reported result**All outcomesUnclear selection criteria for establishing baseline similarities between groups. PT/APTT may be missing from baseline characteristics\
Reported results are in keeping with those specified in the study methodsLowTable 5ROBINS‐I assessment: Izadi 2009**ROBINS‐I assessmentReference**: [@CD012713-bbs2-0012]**Risk of bias domainAssessments by outcomeCommentConclusionBias due to confounding**Mortality, length of hospital stay, transfusion, withdrawal of treatment: serious risk of bias due to baseline confoundingTime from onset of symptoms adjusted for by stratification into early/late ribavirin Baseline characteristics and severity of disease are not assessed, measured or controlled for\
Multiple regression models used to identify factors predictive of mortality. Regression does not adjust for severity and prognostic factors for the efficacy of ribavirin\
Adjusted estimates of effect not included in analysis due to linear regression not outlined clearly, although it is unlikely to control for confounding of the effect of ribavirinSerious**Bias in selection of participants into the study**Mortality, length of hospital stay, transfusion, withdrawal of treatment: low risk of biasUnclear if selection into the study was based on participant\'s characteristics observed after the start of the study; retrospective designModerate**Bias in classification of interventions**All outcomesNot recordedModerate**Bias due to deviations from intended interventions**All outcomesNo deviation from intended intervention, as would be the case in usual practice. Most participants received a transfusion ‐ Table 3 shows the proportions of participants who received a transfusion of platelet concentrates, and in some cases fresh frozen plasma and packed erythrocytes. No other aspects of care or co‐interventions are discussed No information on adhering to ribavirin treatmentLow**Bias due to missing data**All outcomes: seriousOutcome data (mortality or cured) reported for all 63 participants according to treatment groupLow**Bias in selection of the reported result**All outcomesAlthough no protocol available or prespecified outcomes, the authors state that they attempted to assess the effect of ribavirin in reducing mortalityModerate

One study ([@CD012713-bbs2-0003]) controlled for confounding by matching baseline characteristics of 10 cases with 40 controls ([Table 8](#CD012713-tbl-0008){ref-type="table"}). One mixed retrospective/prospective cohort study ([@CD012713-bbs2-0005]) established a severity scoring index and stratified results using this as a way of controlling for confounding by severity. Time from onset of symptoms to diagnosis was addressed by not prescribing ribavirin to anyone with more than seven days history of symptoms ([Table 9](#CD012713-tbl-0009){ref-type="table"}). One historically‐controlled cohort study ([@CD012713-bbs2-0006]) established similar baseline characteristics between cohorts. The use of a historical control arm at the onset of an epidemic establishes a difference in the quality of supportive care between groups. The time period elapsed was only one year, so we classified this as serious and not critical confounding ([Table 10](#CD012713-tbl-0010){ref-type="table"}). One retrospective cohort study ([@CD012713-bbs2-0012]) stratified mortality outcome by time from onset of symptoms to administration of ribavirin ([Table 11](#CD012713-tbl-0011){ref-type="table"}). This study performed a regression analysis, although this was designed to identify predictive factors for mortality and not to control for confounding. We classified all four non‐randomized studies included in the main effects analysis as being at serious risk of bias for the domain of confounding.

##### Bias in selection of participants into the study {#CD012713-sec5-0014}

In [@CD012713-bbs2-0003] ([Table 8](#CD012713-tbl-0008){ref-type="table"}), participants were matched by their baseline severity according to clinical presentation and laboratory values. The trial authors did not adequately describe the matching process, although stated the controls were selected \"at random\". The lack of clarity meant that we classified this study as being at serious risk of bias in this domain.

In [@CD012713-bbs2-0005] ([Table 9](#CD012713-tbl-0009){ref-type="table"}), participants in the control group were selected based on time from onset of symptoms (more than seven days) and clinical contraindication. Both are prognostic factors that predict whether the individual receives the intervention. We therefore judged this as being at serious risk of bias for this domain. We did not judge this domain as critical, because baseline severity was established, measured, and sufficiently comparable to garner useful data from the study.

In [@CD012713-bbs2-0006] ([Table 10](#CD012713-tbl-0010){ref-type="table"}), selection of participants was not related to the intervention, outcome, or any prognostic factor; the historical control group may have confounded results. We therefore judged this domain to be at serious risk of bias. We did not judge this domain as critical, because baseline severity was established, measured, and sufficiently comparable to garner useful data from the study.

In [@CD012713-bbs2-0012] ([Table 11](#CD012713-tbl-0011){ref-type="table"}), it was unclear if selection into the study was based on participants\' characteristics observed after the start of the retrospective study design.

##### Bias in classification of interventions {#CD012713-sec5-0015}

We judged all studies to be at low risk of bias, as the doses and methods of administration of ribavirin were well‐defined.

##### Bias due to deviations from intended interventions {#CD012713-sec5-0016}

We judged all studies to be at low risk of bias. In none of the studies were there deviations from the intended intervention other than what would be expected in normal practice.

##### Bias due to missing data {#CD012713-sec5-0017}

In [@CD012713-bbs2-0005] there were some missing outcome data not described in the text. The missing data were related to numbers of participants receiving co‐administration of corticosteroids with ribavirin. We judged the balance of missing data across groups as unclear, as there was insufficient documentation explaining this. We therefore classed this study as being at serious risk of bias in this domain.

##### Bias in measurement of outcomes {#CD012713-sec5-0018}

We judged all studies to be at low risk of bias. Whilst investigators will have been aware of the intervention status of the participants (if they received ribavirin or not), none of the measured outcomes were subjective and thus prone to bias.

##### Bias in the selection of reported result {#CD012713-sec5-0019}

[@CD012713-bbs2-0003] and [@CD012713-bbs2-0006] used unclear criteria to establish similar baseline characteristics between arms. Most of the expected clinical and laboratory criteria were included, but a severity score would be more comprehensive. Whilst severity indices have been developed since the publication of these papers, an accepted severity index was available at the time ([@CD012713-bbs2-0147]). We therefore classed both studies as being at moderate risk of bias in this domain.

### Subsidiary descriptive analysis {#CD012713-sec3-0022}

We classified all 18 studies included in the descriptive analysis as being at critical risk of bias due to confounding, as described in [Table 7](#CD012713-tbl-0007){ref-type="table"}. All of these studies were retrospective cohorts by design. The main reason for this was the failure to control for baseline confounding due to severity of disease. Most studies did not describe important baseline characteristics in intervention and control groups.

Effects of interventions {#CD012713-sec2-0010}
------------------------

See: [Table 1](#CD012713-tbl-0001){ref-type="table"}; [Table 2](#CD012713-tbl-0002){ref-type="table"}

Our main effects analysis included one RCT and four non‐randomized studies. The remaining 18 studies, which we assessed as being at critical risk of bias, are used in a subsidiary descriptive analysis for our primary outcome of mortality.

### Ribavirin versus no ribavirin {#CD012713-sec3-0023}

#### Mortality {#CD012713-sec4-0009}

One RCT and three non‐randomized studies were included that compared the effect on mortality of ribavirin and no ribavirin in participants with CCHF ([Figure 3](#CD012713-fig-0003){ref-type="fig"}).Figure 3Forest plot of Ribavirin versus no ribavirin, outcome: mortality.

##### RCT {#CD012713-sec5-0020}

One RCT of 136 participants ([@CD012713-bbs2-0014]) found no statistically significant effect in favour of either ribavirin or no ribavirin (RR 1.13, 95% CI 0.29 to 4.32; [Analysis 1.1](#CD012713-fig-00101){ref-type="fig"}).

##### Non‐randomized studies {#CD012713-sec5-0021}

One mixed retrospective and prospective cohort study of 281 participants stratified risk of death by severity of disease ([@CD012713-bbs2-0005]). No deaths occurred in 103 mild cases and risk ratios were therefore not calculable. In 152 moderate cases (subgroup 2) ribavirin reduced mortality (RR 0.09, 95% CI 0.02 to 0.50). In 26 severe patients no effect of ribavirin on mortality was seen (RR 0.79, 95% CI 0.44 to 1.41; [Analysis 1.2](#CD012713-fig-00102){ref-type="fig"}, [Figure 4](#CD012713-fig-0004){ref-type="fig"} ). The two participants in the severe disease strata control group were unable to take oral ribavirin due to gastro‐intestinal bleeding, despite an intention to treat them with ribavirin.Figure 4Forest plot of comparison: 1 Ribavirin versus no ribavirin, outcome: 1.2 Mortality stratified by severity of disease ([@CD012713-bbs2-0005]).

One cohort study with a historical control arm of 218 participants had similar baseline characteristics in terms of severity of disease and time from onset of symptoms ([@CD012713-bbs2-0006]). This study showed no statistically significant benefit of ribavirin on mortality (RR 0.60, 95% CI 0.26 to 1.38; [Analysis 1.1](#CD012713-fig-00101){ref-type="fig"})

One retrospective matched cohort study of 50 participants used a matched design where those who received ribavirin were randomly matched to a control group with similar baseline characteristics ([@CD012713-bbs2-0003]). In this study no statistically significant effect was seen (RR 1.33, 95% CI 0.32 to 5.64; [Analysis 1.1](#CD012713-fig-00101){ref-type="fig"}).

In a pooled analysis of these three non‐randomized studies we found no statistically significant effect (RR 0.72, 95% CI 0.41 to 1.28; 549 participants; [Analysis 1.1](#CD012713-fig-00101){ref-type="fig"}; [Figure 3](#CD012713-fig-0003){ref-type="fig"}). With few events and wide CIs containing clinically appreciable benefit and harm, it is not possible to draw a conclusion of benefit or of no effect from the available evidence. Given the concerns over the internal validity of the studies, this further decreases our confidence in the effect estimate.

In summary, it is uncertain whether ribavirin reduces mortality, because the certainty of the evidence is very low from both the RCT and the non‐randomized studies ([Table 1](#CD012713-tbl-0001){ref-type="table"}).

#### Length of hospital stay {#CD012713-sec4-0010}

One non‐randomized study (retrospective matched cohort design) and one RCT met our inclusion criteria and evaluated the effect of ribavirin on length of hospital stay in participants with CCHF receiving ribavirin or not ([@CD012713-bbs2-0014]; [@CD012713-bbs2-0003]; [Analysis 1.3](#CD012713-fig-00103){ref-type="fig"}; [Figure 5](#CD012713-fig-0005){ref-type="fig"}).Figure 5Forest plot of ribavirin versus no ribavirin, outcome: length of hospital stay (days).

##### RCT {#CD012713-sec5-0022}

[@CD012713-bbs2-0014] showed no effect of ribavirin on the length of hospital stay in days (MD 0.70, 95% CI ‐0.39 to 1.79; 136 participants; [Analysis 1.3](#CD012713-fig-00103){ref-type="fig"}).

##### Non‐randomized studies {#CD012713-sec5-0023}

[@CD012713-bbs2-0003] showed no effect of ribavirin on the length of hospital stay in days (MD ‐0.80, 95% CI ‐2.70 to 1.10; 50 participants; [Analysis 1.3](#CD012713-fig-00103){ref-type="fig"}).

In summary, we do not know if ribavirin reduces the length of stay in hospital, as the certainty of the evidence is very low ([Table 1](#CD012713-tbl-0001){ref-type="table"}).

#### Requirement for transfusion {#CD012713-sec4-0011}

One included RCT compared the effect of ribavirin with no ribavirin on the need for transfusion of blood products in participants with CCHF ([@CD012713-bbs2-0014]). There was no statistically significant difference in requirement for transfusion of platelets between treated and untreated participants in the RCT (RR 1.23, 95% CI 0.77 to 1.96; 136 participants; [Analysis 1.4](#CD012713-fig-00104){ref-type="fig"}).

#### Withdrawal of treatment due to adverse events {#CD012713-sec4-0012}

One study included in the primary analysis reported on adverse events leading to discontinuation of treatment. One participant among 44 who received ribavirin and corticosteroids discontinued ribavirin due to elevated amylase levels ([@CD012713-bbs2-0005]).

#### Serious adverse events {#CD012713-sec4-0013}

No studies in the primary analysis reported on adverse events.

### Timing of administration of ribavirin: early versus late ribavirin {#CD012713-sec3-0024}

#### Mortality {#CD012713-sec4-0014}

One non‐randomized study (retrospective cohort) was included that addressed the timing of administration of ribavirin alongside supportive care and mortality ([@CD012713-bbs2-0012]).

[@CD012713-bbs2-0012] outlined an association between reduced mortality in those who received supportive care and ribavirin less than four days since the onset of any symptoms compared to those receiving supportive care and ribavirin after four days (RR 0.39, 95% CI 0.16 to 0.95; 63 participants; [Analysis 2.1](#CD012713-fig-00201){ref-type="fig"}; [Figure 6](#CD012713-fig-0006){ref-type="fig"}).Figure 6Forest plot early versus late ribavirin, outcome: mortality in early versus late ribavirin.

Whilst an association was seen between early supportive care and ribavirin and reduced mortality in one included study at serious risk of bias, we are uncertain if early ribavirin is more effective than late ribavirin in treating CCHF. Separating the effect of early presentation to hospital, early diagnosis and early supportive care from the effect of early ribavirin treatment is very difficult without an adequately‐powered randomised study.

### Subsidiary descriptive analyses {#CD012713-sec3-0025}

#### Ribavirin versus no ribavirin {#CD012713-sec4-0015}

In the subsidiary descriptive analysis we explored the effect of confounding on the effect estimates for ribavirin versus no ribavirin. We included 10 studies at critical risk of bias that reported mortality outcomes. We established a non‐overlapping sample using the methods described in [Appendix 2](#CD012713-sec2-0016){ref-type="app"} and present these in a forest plot alongside the single RCT and cohort studies at serious risk of bias ([Analysis 3.1](#CD012713-fig-00301){ref-type="fig"}; [Figure 7](#CD012713-fig-0007){ref-type="fig"}). In these studies with a critical risk of bias, the point estimates shows an effect skewed towards benefit for ribavirin (1 RCT; RR 1.13, 95% CI 0.29 to 4.32; 136 participants; 3 non‐randomized studies at serious risk of bias; RR 0.72, 95% CI 0.42 to 1.28; 549 participants; 10 non‐randomized studies at critical risk of bias RR 0.43, 95% CI 0.22 to 0.86; 1214 participants). There was also increasing heterogeneity (NRS serious risk of bias I^2^ statistic = 0%; NRS critical risk of bias I^2^ statistic = 58%). This supports the conclusions of a previous meta‐analysis ([@CD012713-bbs2-0145]) that the effect seen is likely to be attributable to confounding and that no evidence of benefit could be drawn. Secondly, our descriptive analysis demonstrates that a critical failure to control for confounding is associated with an increase in heterogeneity and inconsistency between studies.Figure 7Forest plot of subsidiary descriptive analysis: ribavirin versus no ribavirin, outcome: mortality.

#### Early versus late supportive care with ribavirin {#CD012713-sec4-0016}

In the subsidiary descriptive analysis of early versus late ribavirin, we explored the effect of confounding of the effect estimates. We included four studies at critical risk of bias and present these in a forest plot alongside the single non‐randomized study at serious risk of bias ([Analysis 4.1](#CD012713-fig-00401){ref-type="fig"}; [Figure 8](#CD012713-fig-0008){ref-type="fig"}).Figure 8Forest plot of comparison: 4 Subsidiary descriptive analysis: early versus late supportive care with ribavirin, outcome: 4.1 Mortality stratified by study type.

Our subsidiary descriptive analysis showed an association between early supportive care with ribavirin and a reduction in mortality in studies with critical risk of bias (4 NRS; RR 0.57, 95% CI 0.38 to 0.85; 431 participants), there was no difference in effect compared to the study at serious risk of bias (1 NRS; RR 0.39, 95% CI 0.16 to 0.95; 63 participants; I^2^ statistic ^=^ 0%).

Discussion {#CD012713-sec1-0006}
==========

Summary of main results {#CD012713-sec2-0011}
-----------------------

See [Table 1](#CD012713-tbl-0001){ref-type="table"}; [Table 2](#CD012713-tbl-0002){ref-type="table"}.

Five studies met the inclusion criteria for our main effects analysis. These was one RCT with 136 participants and four non‐randomized studies with 612 participants. We judged all four non‐randomized studies to have serious risk of bias by ROBINS‐I. There were a further 18 non‐randomized studies classified at critical risk of bias which we included in a subsidiary descriptive analysis. None of these studies attempted to control for confounding.

We do not know if ribavirin reduces mortality (very low‐certainty evidence).

We do not know if ribavirin is more effective when given early with supportive care rather than late with supportive care (very low‐certainty evidence), and we do not know if ribavirin reduces the length of stay in hospital (very low‐certainty evidence).

In terms of possible adverse effects, we do not know if it reduces the risk of patients needing platelet transfusions (very low‐certainty evidence), and we do not know what the adverse effects of treating CCHF with ribavirin are, because there is a lack of data for this outcome.

In the subsidiary descriptive analysis of studies with a critical risk of bias, the point estimates show an effect skewed towards benefit for ribavirin, as well as increasing heterogeneity.

Overall completeness and applicability of evidence {#CD012713-sec2-0012}
--------------------------------------------------

This review includes a single RCT and 22 non‐randomized studies from multiple countries in Europe and Asia. We found no studies from Africa, where CCHF is also endemic.

There is insufficient reliable evidence to be confident of the effects of ribavirin on mortality, length of hospital stay or the need for transfusion of blood products. There is insufficient high‐quality evidence to draw conclusions about the likelihood of serious adverse events occurring when administering ribavirin to people infected with CCHF. Ribavirin is frequently used in the treatment of hepatitis C and the side‐effect profile is well established ([@CD012713-bbs2-0117]). However, given different dosing schedules and the differences in the length of use of ribavirin, we do not think this evidence is sufficiently generalizable to CCHF.

We wondered whether the non‐randomized studies would be sufficient to show a benefit for ribavirin if indeed they had a very large effect on mortality and were of sufficient quality. However, all but four of the studies were at critical risk of bias, which means drawing inferences from these studies is not possible ([@CD012713-bbs2-0146]). In those non‐randomized studies not at critical risk of bias, the evidence base is not of sufficient robustness to draw conclusions about benefit or harm, given our concerns about the internal validity of the studies and imprecision of the effect estimates.

### Certainty of the evidence {#CD012713-sec3-0026}

The overall certainty of the evidence for all outcomes was very low. Any estimate of effect is highly uncertain and is likely to change with further research on the treatment of CCHF. Most research done in this area is of non‐randomized designs and is critically compromised by uncontrolled confounding and small sample sizes. Because of this, we are unable to reach any conclusions on the efficacy of ribavirin for treating CCHF.

For mortality, the single RCT, which was the study with the most reliable internal validity and which we felt provided the most reliable effect estimate, was at high risk of bias and underpowered to show an effect, with few events. As a result we downgraded it to very low‐certainty evidence for the outcome of mortality.

For mortality in early versus late ribavirin, all studies were of a non‐randomized design at serious risk of bias. The pooled effect estimate included few events and broad CIs, which meant we downgraded the evidence to very low certainty.

For length of hospital stay, the single RCT was at high risk of bias and underpowered to show an effect, with few events. We therefore downgraded it to very low‐certainty evidence for this outcome.

For the requirement for transfusion of blood products, the single RCT was at high risk of bias and underpowered to show an effect, with few events. We therefore downgraded it to very low certainty evidence for this outcome.

Potential biases in the review process {#CD012713-sec2-0013}
--------------------------------------

We have minimized the effect of confounding bias on the effect estimates in the non‐randomized studies by only presenting those at serious, moderate, high, low or unclear risk of bias in the main analysis. To describe the effect of confounding we conducted a subsidiary analysis only including those studies at critical risk of bias. We used the latest tools in assessing risk of bias in non‐randomized studies. We sought guidance from specialist methodologists developing the ROBINS‐I tool to aid our processes. Despite these efforts, we included no studies in this review with a low risk of bias, which means that confounding is still likely to bias any estimates in the main effects analysis.

The included studies populations largely came from Turkey and Iran, with little evidence available from other countries, although we attempted to include a broad range of geographic locations by searching extensively for literature and by including a PhD thesis from Russia ([@CD012713-bbs2-0018]).

Agreements and disagreements with other studies or reviews {#CD012713-sec2-0014}
----------------------------------------------------------

A previous systematic review ([@CD012713-bbs2-0145]) concluded that there was no clear evidence of benefit from the data then available, as non‐randomized studies were heavily confounded. In our review we have tried to stratify analysis by different degrees of confounding in the studies. This analysis agrees with the opinion of the authors of the Soares‐Weiser review that the effect seen in their meta‐analysis was likely to have been due to confounding in non‐randomized studies.

[@CD012713-bbs2-0145] included two further studies not included in our review. We excluded these studies because of a sample size of less than 10 participants ([@CD012713-bbs2-0053]), and the lack of a comparator arm ([@CD012713-bbs2-0135]). See the [Excluded studies](#CD012713-sec3-0020){ref-type="sec"} section.

We agree with the assessment of the authors of the [@CD012713-bbs2-0114] review about the internal validity of the included studies and the effect of systematic bias on the effect estimate. We further agree that the results of a meta‐analysis of flawed studies cannot be used as evidence of an effect, and that a randomised controlled trial is needed and ethically justified, given the ambiguity of observational studies.

All studies included in the [@CD012713-bbs2-0114] systematic review are included in our review.

We agree with the two previous systematic reviews on this topic ([@CD012713-bbs2-0145]; [@CD012713-bbs2-0114]). We cannot draw conclusions about the efficacy of ribavirin for treating Crimean Congo haemorrhagic fever using the data currently available. This is largely attributable to too few studies that adequately control for confounding and the lack of a reliable RCT. Any estimate of effect based on currently available data is very uncertain.

### Research in outbreaks {#CD012713-sec3-0027}

In a broader sense, the current status of the evidence for ribavirin in CCHF highlights the difficulties when non‐randomized studies or consensus is used to establish a treatment in the absence of reliable evidence. Once established as standard practice, clinicians feel uneasy about the ethics of conducting a placebo controlled trial whether reliable evidence of efficacy exists or not. This is made more acute because of a previous lack of preparedness for experimental research therapeutics in outbreak situations. In 2016 WHO issued guidance on managing ethical issues in infectious disease outbreaks which highlights the need to learn as much as possible as quickly as possible and that in such situations where no proven treatment exists research should be conducted using rigorous methodology that is capable of providing valid results ([@CD012713-bbs2-0151]).

Whilst monitored use of experimental or unproven therapies can be ethically justifiable in outbreak situations provided; 1) no proven effective treatment exists; 2) it is not possible to initiate clinical studies immediately; 3) data providing preliminary support of the intervention's efficacy and safety are available; 4) the relevant country authorities, as well as an appropriately qualified ethics committee, have approved such use; 5) adequate resources are available to ensure that risks can be minimized; 6) the patient's informed consent is obtained; and 7) the emergency use of the intervention is monitored and the results are documented and shared in a timely manner with the wider medical and scientific community ([@CD012713-bbs2-0151]). It is important always to be clear that no harm is likely, considering the potential for causing harm is important as sometimes there is a perception that any intervention will help because of the high mortality, however, a harmful intervention could push case fatality rates even higher as well as potentially costing valuable time and resources.

As this review demonstrates, establishing efficacy of a therapeutic in acute infectious diseases using observational or non‐randomised data is difficult and results can be unreliable. As such the ability to conduct methodologically rigorous research that is able to demonstrate efficacy should be a requirement of any use of unproven therapeutics in outbreak situations.

Authors\' conclusions {#CD012713-sec1-0007}
=====================

We do not know from the current literature if ribavirin is an effective treatment for CCHF. Most research on this question is of a non‐randomized design and is critically confounded. Any estimates of effect based on the existing literature is highly uncertain and likely to change with further methodologically rigorous research.This review improves on the previous systematic reviews by including all the relevant information from observational studies and assessing them systematically. We have used the latest methods examining confounding and other important methodological aspects important in assessing the findings of non randomised studies looking at the effects of ribavirin in CCHF.There remains considerable controversy on the effects of ribavirin in CCHF and whether to use it, reflecting true uncertainty in the field, with some strong advocates ([@CD012713-bbs2-0008]); and others recommend supportive care only ([@CD012713-bbs2-0013]). These clear variations in practice and viewpoints and the lack of any clear message from this independent systematic review of the of the evidence point us in the direction of a randomised clinical trial to establish or disprove the efficacy of ribavirin, as has been suggested previously ([@CD012713-bbs2-0145]; [@CD012713-bbs2-0114]).
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MEDLINE (PubMed) {#CD012713-sec3-0028}
================

\#1 Search \"Hemorrhagic Fever, Crimean\"\[Mesh\] OR \"Hemorrhagic Fever Virus, Crimean‐Congo\"\[Mesh\]

\#2 Search CCHF \[Title/Abstract\] OR \"Crimean Congo hemorrhagic fever\" \[Title/Abstract\] or \"Crimean Congo haemorrhagic fever\" \[Title/Abstract\]

\#3 Search \#1) or \#2

\#4 Search \"ribavirin\"\[MeSH Terms\] OR \"ribavirin\" \[Title/Abstract\]

\#5 Search \#3) and \#4

Cochrane Library {#CD012713-sec3-0029}
================

Cochrane Central Register of Controlled Trials {#CD012713-sec3-0030}
==============================================

ID Search Hits

\#1 MeSH descriptor: \[Hemorrhagic Fever Virus, Crimean‐Congo\] explode all trees

\#2 MeSH descriptor: \[Hemorrhagic Fever, Crimean\] explode all trees

\#3 Crimean‐Congo hemorrhagic fever

\#4 Crimean‐Congo haemorrhagic fever

\#5 \#1 or \#2 or \#3 or \#4

Embase 1947‐Present, updated daily {#CD012713-sec3-0031}
==================================

Search strategy:

‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐‐

1 Crimean Congo hemorrhagic fever/

2 Crimean‐Congo hemorrhagic fever.mp.

3 Crimean congo hemorrhagic fever virus.mp. or Crimean‐Congo hemorrhagic fever virus/

4 CCHF.mp.

5 1 or 2 or 3 or 4

6 ribavirin/ or ribavirin.mp.

7 5 and 6

**[(from Web of Science Core Collection)]{.ul}**

You searched for: **TOPIC:** (\"Crimean Congo hemorrhagic fever\" or CCHF) *AND***TOPIC:** (ribavirin or treatment)

**Timespan:** All years. **Indexes:** SCI‐EXPANDED, SSCI, CPCI‐S, CPCI‐SSH, IC.

**Interface ‐ EBSCOhost Research Databases**

CINAHL {#CD012713-sec3-0032}
======

**\#Query**S4S2 AND S3S3TX ribavirin OR MH ribavirinS2\"Crimean Congo hemorrhagic fever OR Crimean‐Congo haemorrhagic fever\"S1\"Crimean Congo hemorrhagic fever OR Crimean‐Congo haemorrhagic fever\"

Methods {#CD012713-sec3-0033}
=======

We conducted a subsidiary descriptive analysis to quantify and help explain the effect of confounding on the effect estimate for the outcome of mortality. We included all non‐randomized studies at critical risk of bias in this descriptive analysis.

We established the sample from non‐overlapping studies as set out below . We made the following decisions on overlapping samples based on the following decision rules:

We considered populations to be overlapping if they were conducted in:

the same country, region and/or hospital; andthe same or overlapping time periods; andthe same population characteristics (for example, age); andthe same intervention (for example, route of administration).

We did not consider author names as indicators of potentially overlapping populations.

Where studies\' populations potentially overlapped, we contacted study authors for confirmation.

We selected the study with the largest number of participants that most directly assessed the review question

Risk of bias {#CD012713-sec3-0034}
============

We classified all studies as being at critical risk of bias due to confounding. None of the studies controlled for confounding due to severity of disease or length of time from onset of symptoms to administration of ribavirin. These confounding factors were set out a priori and full details are given in [Table 7](#CD012713-tbl-0007){ref-type="table"}.

Results of sensitivity analysis {#CD012713-sec3-0035}
===============================

We included 10 studies at critical risk of bias ([@CD012713-bbs2-0001]; [@CD012713-bbs2-0008]; [@CD012713-bbs2-0017]; [@CD012713-bbs2-0004]; [@CD012713-bbs2-0010]; [@CD012713-bbs2-0018]; [@CD012713-bbs2-0021]; [@CD012713-bbs2-0023]; [@CD012713-bbs2-0024]; [@CD012713-bbs2-0002]), that did not have overlapping populations using the methods outlined above.

The studies considered and deemed to be overlapping are set out below\*.

**Ribavirin versus no ribavirin: mortality**[@CD012713-bbs2-0001]**1999‐2004IranBoo‐Ali Hospital255Children**[@CD012713-bbs2-0019]\
**(overlaps with**[@CD012713-bbs2-0001]**)**1999‐2006IranBoo‐Ali Hospital25Children[@CD012713-bbs2-0015]\
**(overlaps with**[@CD012713-bbs2-0001]**)**1999‐2001IranMulti‐region187Includes Sistan‐Baluchestan province, where Boo‐Ali hospital is located. Although age range not reported for this study, 69% \< 33 years, and substantial overlap with Alavi‐Naini is suspected[@CD012713-bbs2-0008]**2002‐2004TurkeyAnkara45Severe cases only**[@CD012713-bbs2-0007]**(overlaps with**[@CD012713-bbs2-0008]**)2002‐2003TurkeyAnkara35**‐[@CD012713-bbs2-0024]**2005‐2010TurkeyAnkara50Children**[@CD012713-bbs2-0011]\
**(overlaps with**[@CD012713-bbs2-0024]**)**2005‐2013TurkeyAnkara26Children[@CD012713-bbs2-0022]\
**(overlaps with**[@CD012713-bbs2-0024]**)**2009‐2014TurkeyAnkara46Children[@CD012713-bbs2-0004]**2006TurkeyAnkara25IV RBV only (all other studies were oral or not reported)**[@CD012713-bbs2-0023]**2007‐2012TurkeyAnkara243Mean age 51 years (SD 18) and 48 years (SD 17), so most participants suspected to be adults, and not to overlap substantially with**[@CD012713-bbs2-0024][@CD012713-bbs2-0009]\
**(overlaps with**[@CD012713-bbs2-0023]**)**2007‐2010TurkeyAnkara100‐[@CD012713-bbs2-0013]\
**(overlaps with**[@CD012713-bbs2-0023]**)**2007‐2010TurkeyAnkara81‐[@CD012713-bbs2-0010]**2007‐2008TurkeyAydin26**‐[@CD012713-bbs2-0017]**2002‐2004TurkeyErzurum60**‐[@CD012713-bbs2-0021]**2004‐2007TurkeySamsun52**‐[@CD012713-bbs2-0002]**2008‐2011TurkeySamsun54Children**[@CD012713-bbs2-0018]**1999‐2008RussiaStavropol404**‐

\*Studies in bold included in descriptive analysis.

The effects are described and discussed in the main text.

The effect observed was largely driven by two studies ([@CD012713-bbs2-0001]; [@CD012713-bbs2-0018]).

We considered [@CD012713-bbs2-0001] to be at critical risk of bias, as there was no control for severity of disease as a confounder. The intervention and control groups were highly unbalanced and we therefore had concerns that selection of participants into the two arms was closely related to severity of disease. This is important in the context of CCHF, given the likelihood of patients developing gastro‐intestinal bleeding and therefore being unable to receive oral ribavirin ([@CD012713-bbs2-0042]).

[@CD012713-bbs2-0018] is a retrospective cohort study using historical controls. The control group was selected from a period of several years before ribavirin was available in Stavropol. We rated this design as critically confounded, as there will have been variable supportive care over this period, and given the emerging nature of the CCHF epidemic as physicians gained more experience in treating this disease and supportive care will have improved outcomes over time.

Risk of bias: ROBINS‐I {#CD012713-sec3-0036}
======================

Target trial {#CD012713-sec4-0017}
------------

A designated target trial was theoretically specified to aid in assessment of risk of bias.([@CD012713-bbs2-0146])

Design: individually randomised

Participants: patients with confirmed CCHF

Experimental intervention: oral or parenteral ribavirin at WHO recommended dose.

Comparator: placebo control group with similar supportive care setting and protocols established, for example, for administration of blood products.

The aim of the study is to assess the effect of assignment to the intervention.

We applied an interpretation of domain‐level and overall risk of bias according to ROBINS‐I guidance. We made all judgements based on the guidance provided by signalling questions and reaching risk of bias judgements in ROBINS‐I ([Table 12](#CD012713-tbl-0012){ref-type="table"}; [@CD012713-bbs2-0146]).Table 6ROBINS‐I Interpretation of domain level and overall risk of bias judgements**JudgementWithin each domainAcross domainsCriterionLow risk of bias**The study is comparable to a well‐performed randomised trial with regard to this domainThe study is comparable to a well‐performed randomised trialThe study is judged to be at low risk of bias for all domains**Moderate risk of bias**The study is sound for a non‐randomized study with regard to this domain but cannot be considered comparable to a well‐performed randomised trialThe study provides sound evidence for a non‐randomized study but cannot be considered comparable to a well‐performed randomised trialThe study is judged to be at low or moderate risk of bias for all domains**Serious risk of bias**the study has some important problems in this domainThe study has some important problemsThe study is judged to be at serious risk of bias in at least one domain, but not at critical risk of bias in any domain**Critical risk of bias**the study is too problematic in this domain to provide any useful evidence on the effects of interventionThe study is too problematic to provide any useful evidence and should not be included in any synthesisThe study is judged to be at critical risk of bias in at least one domain**No information**No information on which to base a judgement about risk of bias for this domainNo information on which to base a judgement about risk of biasThere is no clear indication that the study is at serious or critical risk of bias and there is a lack of information in one or more key domains of bias (a judgement is required for this)[^4]

Criteria used to assess risk of bias within ROBINS‐I tool {#CD012713-sec3-0037}
=========================================================

Death, death in those with early or late administration of ribavirin, length of hospital stay and requirement for transfusion were considered sufficiently related to have similar confounding factors associated with them. We considered classification of risk of bias for these outcomes using the following domains. We gave separate consideration to serious adverse events and withdrawal of treatment.

Listing of confounding domains {#CD012713-sec4-0018}
------------------------------

Controlling for baseline confounding is an issue that affects most non‐randomized studies of interventions (NRSIs). Baseline confounding occurs when one or more prognostic variables (factors that predict the outcome of interest) also predict the intervention received at baseline ([@CD012713-bbs2-0146]). As part of the ROBINS‐I assessment, we considered the length of time from onset of symptoms to start of ribavirin and severity of disease as confounding domains. We made the decisions to include these as confounding domains based on extensive debate in the literature ([@CD012713-bbs2-0042]). We listed co‐interventions that could differ between intervention groups impacting on outcomes as quality of supportive care.

For the purposes of assessing confounding we considered all except one of our outcomes sufficiently related to have common confounding factors and so they were assessed in a group, as in the ROBINS‐I guidance. ([@CD012713-bbs2-0146]) The only outcome assessed separately was serious adverse events.

### Length of time from onset of symptoms {#CD012713-sec5-0024}

The pathology of CCHF presents in multiple stages with viraemia labile and typically present early in the disease. Supportive treatment early in the condition is therefore important and any antiviral effect is likely to be more effective if antivirals are initiated earlier in the disease course.

We considered any study that did not take into account the length of time since onset of symptoms before starting ribavirin to be at risk of bias.

### Severity of disease {#CD012713-sec5-0025}

CCHF can present at a variety of severities. If ribavirin were only to be prescribed to patients with severe disease, any analysis would be biased toward ribavirin being harmful. Furthermore, treatment of all CCHF cases with ribavirin except for those in whom it was contraindicated (for example, patients with haematemesis, other significant co‐morbidities or late presentation to medical care) would bias results in showing a false efficacy of ribavirin. Documentation of disease severity and indication for not receiving ribavirin where it is standard practice is therefore critical for any balanced analysis.

### Historical controls and quality of supportive care {#CD012713-sec5-0026}

In any emerging epidemic, it is necessary for medical professionals and institutions to develop and constantly improve the way they treat patients. Given supportive care is of critical importance to the management of CCHF, it follows that improving standards of supportive and nursing care and development of local expertise and management protocols would cause mortality to decline. As such any use of a historical control arm was considered methodologically confounded. The degree to which any use of a historical control arm confounds the estimate of effect and whether this placed a study at serious or critical risk of bias was assessed on a study by study basis.

Bias in selection of participants into the study {#CD012713-sec4-0019}
------------------------------------------------

### Retrospective cohort Studies {#CD012713-sec5-0027}

Information describing how participants were selected into any analysis must be included in any analysis. Failure to do so renders any study at critical risk of bias, due to the risk of selection bias.

Bias in classification of intervention {#CD012713-sec4-0020}
--------------------------------------

Studies were required to define the route of ribavirin which was administered.

Bias due to deviations from intended interventions {#CD012713-sec4-0021}
--------------------------------------------------

Varying length of ribavirin administration may impact outcomes. Studies were required to give information on the duration of treatment. We judged this against WHO‐recommended treatment regimens ([@CD012713-bbs2-0150]).

Bias due to missing data {#CD012713-sec4-0022}
------------------------

Data from all participants should be included in any analysis.

Bias in measurement of outcomes {#CD012713-sec4-0023}
-------------------------------

Outcomes must be well defined within any analysis, for example mortality, or directly measurable, for example laboratory results. Serious adverse events must have an analysis of the degree to which any serious adverse event was attributable to the intervention. This is particularly difficult in ribavirin for CCHF, given the overlap between side effects and the disease process, as previously outlined.

Bias in selection of the reported result {#CD012713-sec4-0024}
----------------------------------------

Reporting of outcomes should be in keeping with a prespecified study protocol. If this was not feasible prespecified outcomes should be made clear in the Methods section.

Comparison 1Ribavirin versus no ribavirinOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Mortality](#CD012713-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Ribavirin versus no ribavirin, Outcome 1 Mortality.4Risk Ratio (M‐H, Random, 95% CI)Subtotals only1.1 RCT1136Risk Ratio (M‐H, Random, 95% CI)1.13 \[0.29, 4.32\]1.2 Non‐randomized studies3549Risk Ratio (M‐H, Random, 95% CI)0.72 \[0.41, 1.28\][2 Mortality stratified by severity of disease (Dokuzoguz 2013)](#CD012713-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Ribavirin versus no ribavirin, Outcome 2 Mortality stratified by severity of disease (Dokuzoguz 2013).1Risk Ratio (M‐H, Random, 95% CI)Totals not selected[3 Length of hospital stay (days)](#CD012713-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Ribavirin versus no ribavirin, Outcome 3 Length of hospital stay (days).2Mean Difference (IV, Random, 95% CI)Totals not selected3.1 RCT1Mean Difference (IV, Random, 95% CI)0.0 \[0.0, 0.0\]3.2 Non‐randomized studies1Mean Difference (IV, Random, 95% CI)0.0 \[0.0, 0.0\][4 Requirement for transfusion (platelets)](#CD012713-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Ribavirin versus no ribavirin, Outcome 4 Requirement for transfusion (platelets).1Risk Ratio (M‐H, Random, 95% CI)Totals not selected

Comparison 2Early versus late supportive care with ribavirinOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Mortality](#CD012713-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Early versus late supportive care with ribavirin, Outcome 1 Mortality.1Risk Ratio (M‐H, Random, 95% CI)Totals not selected

Comparison 3Subsidiary descriptive analysis ‐ Ribavirin versus no ribavirinOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Mortality stratified study type](#CD012713-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Subsidiary descriptive analysis ‐ Ribavirin versus no ribavirin, Outcome 1 Mortality stratified study type.14Risk Ratio (M‐H, Random, 95% CI)Subtotals only1.1 RCT1136Risk Ratio (M‐H, Random, 95% CI)1.13 \[0.29, 4.32\]1.2 Non‐randomized studies (serious risk of bias)3549Risk Ratio (M‐H, Random, 95% CI)0.72 \[0.41, 1.28\]1.3 Non‐randomized studies (critical risk of bias)101214Risk Ratio (M‐H, Random, 95% CI)0.43 \[0.22, 0.86\]

Comparison 4Subsidiary descriptive analysis: early versus late supportive care with ribavirinOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 Mortality stratified by study type](#CD012713-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Subsidiary descriptive analysis: early versus late supportive care with ribavirin, Outcome 1 Mortality stratified by study type.5Risk Ratio (M‐H, Random, 95% CI)Subtotals only1.1 Serious risk of bias163Risk Ratio (M‐H, Random, 95% CI)0.39 \[0.16, 0.95\]1.2 Critical risk of bias4431Risk Ratio (M‐H, Random, 95% CI)0.57 \[0.38, 0.85\]

One additional review author joined the review author team (Nicholas Henschke).

We restructured the [Background](#CD012713-sec1-0002){ref-type="sec"} to the review to add clarity.

We also included studies that compared early to late administration of ribavirin. This is an important part of the debate around the effectiveness of ribavirin as a treatment. We allowed definitions of 'early\' and 'late\' to be determined by the study authors.

We did not include any cohort studies without comparators.

We allowed studies that had co‐interventions other than ribavirin, as long as the indications were the same across all arms of the study.

We clarified that the outcome of death amongst those receiving ribavirin early versus late was a separate comparison, but mortality was still the primary outcome.

We amended the prespecified subgroup analyses. We removed early versus late ribavirin as a subgroup and instead included it as a comparison. This was because it required different study designs.

In our protocol we stated that wherever possible we would combine adjusted measures of effect for non‐randomized studies. One study, [@CD012713-bbs2-0005], used a model to control for confounding of effect due to severity of disease. This resulted in an adjusted OR of 0.04 (0.004 to 0.48), which is an extremely large effect. The small sample size, the size of the adjusted effect, missing data from the corticosteroid analysis, concerns about unmeasured confounding factors such as time from onset of symptoms, and the fact that the study analysed severe patients with gastro‐intestinal haemorrhage per protocol and not by intention‐to‐treat meant that we took a conservative approach to synthesis and presented the non‐adjusted stratified data in a forest plot instead of the adjusted estimate.

We also only included cohort studies if they had more than 10 participants.

Characteristics of included studies \[ordered by study ID\] {#CD012713-sec2-0020}
===========================================================

[@CD012713-bbs2-0001]MethodsRetrospective cohort studyParticipants255/155 confirmed cases Age NR, Gender 22.4% femaleInterventionsRibavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x daily for 6 days oralOutcomesMortalityLocation and datesBoo‐Ali Hospital, Zahedan + Zabol: Sistan‐Baloochestan province, Iran Unclear ‐ whether patients treated at hospital that is source of study June 1999 ‐ February 2004Number of days since onset of symptoms (mean/SD)Mean incubation period 4.4 days (SD = 2.6, range 1 ‐ 14) (whole study population)Supportive therapyNRNotes[@CD012713-bbs2-0002]MethodsRetrospective cohort studyParticipants167 suspected, 54 confirmed cases, mean age 12.8 years (SD = 3.3)InterventionsRibavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x daily for 6 days oralOutcomesMortality, bradycardiaLocation and datesUniversity Faculty of Medicine, Samsun, Turkey; Tertiary care centre CCHF reference centre May 2008 ‐ September 2011Number of days since onset of symptoms (mean/SD)Mean: 3.6 (SD = 2.4) (range = 1 ‐ 15)Supportive therapyFFP, thrombocyte suspension or erythrocyte suspensionNotesChildren[@CD012713-bbs2-0003]MethodsMatched retrospective cohort studyParticipants50 confirmed casesInterventionsRibavirin 4 g/day for 4 days and then 2.4 g/day for 6 days oralOutcomesMortality, length of hospitalisation, requirement for transfusion (PRC), requirement for transfusion (FFP), requirement for transfusion (platelets) ‐ RBV versus no RBVLocation and datesAnkara Numune Education and Research Hospital, Ankara, Turkey 2006 ‐ 2008Number of days since onset of symptoms (mean/SD)Ribavirin 4.3 ± 1.4 (to hospitalisation); Control group 4.4 ± 1.4 (to hospitalisation)Supportive therapyErythrocytes, platelets, FFP, or hydration according to homeostatic statusNotes[@CD012713-bbs2-0004]MethodsCase‐control studyParticipants25 confirmed cases Age NR, Sex NRInterventionsRibavirin loading dosage of 17 mg/kg IV, then 17 mg/kg every 6 h for 4 days, and then 8 mg/kg every 8 h for 6 days Intravenous administrationOutcomesMortality, SAEs, length of hospitalisation, treatment discontinuation, requirement for transfusion (PRC, FFP, platelets)Location and datesAnkara Numune Education and Research Hospital and Sivas Cumhuriyet University Hospital, Ankara, Turkey May ‐ August 2006Number of days since onset of symptoms (mean/SD)NRSupportive therapyNRNotes[@CD012713-bbs2-0005]MethodsProspective and retrospective cohort studyParticipants281 confirmed cases, mean age 47 (SD = 16) (range = 16 ‐ 86), 49% womenInterventionsRibavirin with or without corticosteroids,\
Ribavirin: 4 g daily for 4 days, followed by 2.4 g daily for 6 days; Corticosteroids: 10 mg/m^2^ dexamethasone; oral ribavirin, corticosteroids route NR. Unclear proportions of patients received steroidsOutcomesSeverity scoring index, mortalityLocation and datesAnkara Numune Education and Research Hospital, Ankara, Turkey tertiary centre 2004 ‐ 2011Number of days since onset of symptoms (mean/SD)All patients \< 7 daysSupportive therapyErythrocytes, platelets,and total blood according to homeostasis needsNotes[@CD012713-bbs2-0006]MethodsHistorical control studyParticipants218 confirmed cases,\
Mean age: ribavirin group mean 44.4 (SD = 19.1); No‐ribavirin group mean 40.9 (SD = 16.7), 50% womenInterventionsRibavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x daily for 6 days; Oral (nasogastric tube if oral not possible)OutcomesMortality, length of hospital stay, requirement for transfusion (PRC, FFP, platelets)Location and datesCumhuriyet University; Ankara Numune Training Hospital, Ataturk University Research Hospital; Ondokuz Mayis University, Sivas; Ankara; Erzurum; Samsun, Turkey tertiary centres 2004Number of days since onset of symptoms (mean/SD)Median 5 (range = 1 ‐ 11)Supportive therapyErythrocyte suspensions,platelet suspensions, FFP and other supportive as requiredNotes[@CD012713-bbs2-0008]MethodsRetrospective cohort studyParticipants54 confirmed casesInterventionsRibavirin 4 g 4 x daily for 4 days, and 2.4 g 4 x daily for 6 days; oralOutcomesMortalityLocation and datesAnkara Numune Education and Research Hospital, Ankara, Turkey tertiary centre 2002 ‐ 2004Number of days since onset of symptoms (mean/SD)5.5Supportive therapyErythrocytes, platelets, and total blood according to homeostasis needsNotes[@CD012713-bbs2-0007]MethodsProspective cohort studyParticipants35 confirmed cases Mean age 43 (SD = 17), 51% womenInterventionsRibavirin 4 g 4 x daily for 4 days, and 2.4 g 4 x daily for 6 days; oralOutcomesMortality (severe CCHF cases only)Location and datesAnkara Numune Education and Research Hospital, Ankara, Turkey tertiary centre 2002 ‐ 2003Number of days since onset of symptoms (mean/SD)5.5 (SD = 1.7)Supportive therapyErythrocytes, platelets, and total blood according to homeostasis needsNotes[@CD012713-bbs2-0009]MethodsRetrospective cohort studyParticipants56 confirmed casesInterventionsRibavirin 2 g as an initial loading dose, then 1 g 4 x daily for 4 days, and then 0.5 g 4 x daily for 6 days Oral ribavirinOutcomesMortality, length of hospitalisation, requirement for transfusion (FFP), requirement for transfusion (platelets), SAEsLocation and datesAnkara Training and Research Hospital in Central Anatolia, Ankara, Turkey tertiary centre 2007 ‐ 2010Number of days since onset of symptoms (mean/SD)Early ribavirin, median 2 (range = 1 ‐ 5 days); Late ribavirin, median 5 (range = 4 ‐ 8 days); No ribavirin, median 3 (range 1 ‐ 10 days)Supportive therapyErythrocytes, platelets, FFP, or hydration as neededNotesComparator ‐ late ribavirin[@CD012713-bbs2-0010]MethodsRetrospective cohort studyParticipants61 cases, 26 confirmedInterventionsRibavirin ‐ route and dose NROutcomesMortalityLocation and datesAdnan Menderes, University Medical Faculty, Aydin, Turkey, Hospital/community:18/26 cases admitted to hospitals April 2007 ‐ Jun 2008Number of days since onset of symptoms (mean/SD)NRSupportive therapyNRNotes[@CD012713-bbs2-0011]MethodsRetrospective cohort studyParticipants26 confirmed cases\
Age 10 years ± 2, sex 30.7% femaleInterventionsRibavirin 30 mg/kg as an initial loading dose, followed by 15 mg/kg every 6 h for 4 days, and then 7.5 mg/kg every 8 h for 6 days; oralOutcomesMortalityLocation and datesMaternity and Children's Research and Education Hospital, Ankara, Turkey, tertiary hospital 2005 ‐ 2013Number of days since onset of symptoms (mean/SD)NRSupportive therapyReplacement of fluid and electrolytes, and administration of platelet suspension, FFP and erythrocyte suspensionNotesStudy only included children[@CD012713-bbs2-0012]MethodsRetrospective cohort studyParticipants63 confirmed cases Mean age 29.2 years (range = 11 ‐ 75 years), sex NRInterventionsEarly ribavirin (\< 4 days), late ribavirin (\> 4 days)\
For adults, 2 g of ribavirin had been prescribed initially as a loading dose, followed by 1 g every 6 h for 4 days and then 500 mg every 8 h for 6 days.\
For children, a 30 mg/kg bolus was initially administered, followed by 15 mg/kg every 6 h for 4 days; oralOutcomesMortalityLocation and datesBoo‐Ali Educational Hospital, Zahedan, Iran, tertiary centre, 2000 ‐ 2006Number of days since onset of symptoms (mean/SD)Mean 5.0 (SD = 1.6)Supportive therapyBlood productsNotes[@CD012713-bbs2-0013]MethodsRetrospective cohort studyParticipants81 confirmed cases Mean age: ribavirin group 54 ± 14.98; no‐ribavirin group 42.81 ± 16.50InterventionsRibavirin 2 g loading then 4 g/day maintenance; oral ribavirinOutcomesMortality, requirement for transfusion (FFP, PRC, platelets)Location and datesErciyes University Hospital and Yozgat State Hospital, Kayseri and Yozgat, Turkey, tertiary centre. January 2007 ‐ December 2010Number of days since onset of symptoms (mean/SD)Ribavirin: median = 5 days, No ribavirin: median = 7 daysSupportive therapyErythrocytes, platelets, FFP, or hydration according to homeostatic statusNotesSeverity assessed according to Swanepoel and Ergonul criteria.[@CD012713-bbs2-0014]MethodsRCTParticipants136 confirmed cases Mean age 49.2InterventionsRibavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x daily for 6 days; Oral ribavirinOutcomesMortality, length of hospital stay, requirement for transfusion.Location and datesKaradeniz Hospital, Trabzon, Turkey, tertiary centre; June 2004 ‐ August 2007Number of days since onset of symptoms (mean/SD)Ribavirin: mean 4.5 (SD = 2.5); No ribavirin: mean 3.9 (SD = 2.4)Supportive therapySupportive care and fluid, platelet, FFP, blood products as necessaryNotes[@CD012713-bbs2-0015]MethodsRetrospective cohort studyParticipants139 suspected, 69 confirmed cases\
Age: 68.9% \< 33 years of ageInterventionsRibavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x daily for 6 days; Oral (nasogastric tube of oral not possible)OutcomesMortalityLocation and datesShahid Beheshti University and regional hospitals, Tehran and regions: Sistan Balouchestan, Esfahan, Golestan, Iran Patients treated at \"local hospitals where they had presented\"; June 1999 ‐ September 2001Number of days since onset of symptoms (mean/SD)Mean 4 daysSupportive therapyNRNotes[@CD012713-bbs2-0016]MethodsRetrospective cohort studyParticipants179 cases Age; NRInterventionsOral ribavirin, dose NR; early intervention \< 5 days since onset of symptomsOutcomesMortalityLocation and datesBoo‐Ali Hospital in Zahedan, Zahedan, Iran tertiary centre; Dates NRNumber of days since onset of symptoms (mean/SD)NRSupportive therapyNRNotesConference abstract[@CD012713-bbs2-0017]MethodsRetrospective cohort studyParticipants60 confirmed cases\
Mean age: 40 ± 17 (range = 15 -- 76) yearsInterventionsRibavirin 2000 mg orally initial loading dose, then 1000 mg every 6 h for 4 days, and then 500 mg every 6 h for 6 days; OralOutcomesMortality, duration of hospitalisation, SAEs, requirement for transfusion (PRC), requirement for transfusion (FFP), requirement for transfusion (platelets)Location and datesAtaturk University Research Hospital, Eastern Turkey, Turkey tertiary centre 2002 ‐ 2004Number of days since onset of symptoms (mean/SD)Ribavirin group 6 (SD = 2.27); No‐ribavirin group 6.5 (SD = 3.46)Supportive therapyFluid, platelet, blood, or components were replaced if necessaryNotes[@CD012713-bbs2-0018]MethodsRetrospective cohort study \[PhD thesis\]Participants404 confirmed casesInterventionsRibavirin: 1200 mg if \> 75 kg, 1000 mg if \< 75 kgOutcomesMortalityLocation and datesStavropol\' State Medical Academy, Russia 1999‐2008Number of days since onset of symptoms (mean/SD)Early ribavirin 1 ‐ 3 days; Late ribavirin 2 ‐ 6 daysSupportive therapyBlood products and fluids as indicatedNotes[@CD012713-bbs2-0019]MethodsRetrospective cohort studyParticipants29 confirmed cases Age 5 ‐ 17 yearsInterventionsEarly ribavirin (\< 3 days) 30 mg/kg as an initial dose, then 15 mg/kg every 6 h for 4 days, then 7.5 mg/kg every 8 h for 6 days; Late ribavirin (\> 3 days); Oral ribavirinOutcomesMortalityLocation and datesDepartments of Infectious Diseases, Boo‐Ali Hospital and Iman‐Ali Hospital in Zabol, Province: Sistan and Baluchistan (south‐east Iran), Province: Sistan and Baluchistan (south‐east Iran) tertiary centre June 1999 to February 2006Number of days since onset of symptoms (mean/SD)NRSupportive therapyNRNotesStudy conducted only in children[@CD012713-bbs2-0020]MethodsRetrospective cohort studyParticipants184 cases,\
Age NRInterventionsEarly ribavirin (\< 3 days) 30 mg/kg of body weight as an initial dose and then 15 mg/kg every 6 h for 4 days, and thereafter 7.5 mg/kg for 6 days; Oral Comparator: Late ribavirin (\> 3 days) Same regimen as early ribavirin; OralOutcomesMortalityLocation and datesBoo‐Ali Hospital, Sistan and Baluchestan, in Southeast of Iran, Iran tertiary centre January 2000 ‐ September 2005Number of days since onset of symptoms (mean/SD)NRSupportive therapyNRNotes[@CD012713-bbs2-0021]MethodsRetrospective cohort studyParticipants52 cases (unknown if confirmed)InterventionsRibavirin versus no ribavirin; dose and route not recordedOutcomesMortality, requirement for transfusion (platelets)Location and datesOndokuz Mayis University Faculty of Medicine, Samsun, Turkey tertiary centre 2004 ‐ 2007Number of days since onset of symptoms (mean/SD)Early ribavirin 1 ‐ 4 days, late ribavirin 5 or more daysSupportive therapyNotes[@CD012713-bbs2-0022]MethodsRetrospective cohort studyParticipants46 confirmed cases Mean age: ribavirin 11.6; no ribavirin 7.3InterventionsRibavirin, route and dose NROutcomesMortality, length of hospital stay, requirement for transfusionLocation and datesAnkara Hematology Oncology Children's Training and Research Hospital, Ankara, Turkey tertiary centre January 2009 ‐ Novenber 2014Number of days since onset of symptoms (mean/SD)NRSupportive therapyErythrocytes, FFPNotesChildren only[@CD012713-bbs2-0023]MethodsRetrospective cohort studyParticipants243 cases (unclear if suspected or confirmed)\
Average age NRInterventionsRibavirin, route and dose NROutcomesMortalityLocation and datesAnkara Hospital, Ankara, Turkey tertiary centre, 2007 ‐ 2011Number of days since onset of symptoms (mean/SD)NRSupportive therapySimilar supportive care in 2 departments involved in study ‐ no further information providedNotes[@CD012713-bbs2-0024]MethodsRetrospective cohort studyParticipants50 confirmed casesInterventionsOral ribavirin 30 mg/kg as an initial loading dose, then 15 mg/kg every 6 h for 4 days, and then 7.5 mg/kg every 8 h for 6 daysOutcomesMortalityLocation and datesDr Sami Ulus Maternity and Children's Health and Diseases Training and Research Hospital in Ankara, Turkey; tertiary centre 2005 ‐ 2010Number of days since onset of symptoms (mean/SD)3.5 ± 2.1 (range = 1.0 to 9.0)Supportive therapyErythrocyte/thrombocyte suspension, FFP based on homeostatic status and other supportive careNotes[^5]

Characteristics of excluded studies \[ordered by study ID\] {#CD012713-sec2-0021}
===========================================================

StudyReason for exclusion[@CD012713-bbs2-0025]This was a case series with fewer than 10 participants[@CD012713-bbs2-0026]This was a case series with fewer than 10 participants[@CD012713-bbs2-0027]This is a single case report[@CD012713-bbs2-0028]This was a case series with fewer than 10 participants[@CD012713-bbs2-0029]This was a survey and therefore was a different study design from our inclusion criteria[@CD012713-bbs2-0030]This was a single case report[@CD012713-bbs2-0031]This was a case series with fewer than 10 participants[@CD012713-bbs2-0032]This was a case series with fewer than 10 participants[@CD012713-bbs2-0033]This was a single case report[@CD012713-bbs2-0034]This was a single case report[@CD012713-bbs2-0035]This was a single case report[@CD012713-bbs2-0036]This was a single case report[@CD012713-bbs2-0037]This was a case series with fewer than 10 participants[@CD012713-bbs2-0038]This was a case series with fewer than 10 participants.[@CD012713-bbs2-0039]This was a single case report and discussion[@CD012713-bbs2-0041]This was a survey and therefore did not meet inclusion criteria; it was based on a different study design[@CD012713-bbs2-0040]This was a case report of a single nosocomial transmission.[@CD012713-bbs2-0042]This was a commentary on an included study[@CD012713-bbs2-0043]This was a case series with fewer than 10 participants.[@CD012713-bbs2-0044]This study compared individuals with CCHF to healthy individuals[@CD012713-bbs2-0045]This was a case series with fewer than 10 participants.[@CD012713-bbs2-0046]This was a case series with fewer than 10 cases[@CD012713-bbs2-0047]This was a case series with fewer than 10 cases[@CD012713-bbs2-0048]This was a case series with fewer than 10 participants[@CD012713-bbs2-0049]Translated from Turkish. This was an editorial letter that reported a single case[@CD012713-bbs2-0050]This was a single case report[@CD012713-bbs2-0051]This is an editorial letter written as a reply to comments on an included study[@CD012713-bbs2-0052]This was a case series with fewer than 10 participants[@CD012713-bbs2-0053]This was a case series with fewer than 10 participants.[@CD012713-bbs2-0054]This was a case series with fewer than 10 participants.[@CD012713-bbs2-0055]This was a cohort study that did not compare ribavirin to supportive care only ‐ no comparator arm[@CD012713-bbs2-0056]This was a cohort study that did not compare ribavirin to supportive care only ‐ no comparator arm[@CD012713-bbs2-0057]This was a single case report[@CD012713-bbs2-0058]This reported the effects of administration of hyperimmunoglobulin, not ribavirin.[@CD012713-bbs2-0059]This was a case series with fewer than 10 participants.[@CD012713-bbs2-0060]This reported on the use of ribavirin for prophylaxis but did not report on ribavirin used as treatment for disease[@CD012713-bbs2-0061]This was a single case report[@CD012713-bbs2-0062]This was case series of fewer than 10 participants[@CD012713-bbs2-0063]This was a case series with fewer than 10 participants[@CD012713-bbs2-0064]This was a cohort study that did not compare ribavirin to supportive care only ‐ no comparator arm[@CD012713-bbs2-0065]This was a single case report[@CD012713-bbs2-0066]This was a case series with fewer than 10 participants[@CD012713-bbs2-0067]This was a single case report[@CD012713-bbs2-0068]This was a single case report[@CD012713-bbs2-0069]This was a case series with fewer than 10 participants.[@CD012713-bbs2-0070]This was a case series with fewer than 10 participants.[@CD012713-bbs2-0071]This ongoing study did not include a comparator group where no ribavirin is given.[@CD012713-bbs2-0072]This was a cohort study that did not compare ribavirin to supportive care only ‐ no comparator arm[@CD012713-bbs2-0073]This did not compare use of ribavirin to supportive care only. It did not report mortality as an outcome in a useable way, reporting only a case fatality ratio in those who were transferred to tertiary centres or not transferred. As such this study did not meet our inclusion criteria.[@CD012713-bbs2-0074]This was a case series with fewer than 10 participants[@CD012713-bbs2-0076]This was a single case report[@CD012713-bbs2-0077]This was a single case report[@CD012713-bbs2-0078]This was a case series with fewer than 10 participants[@CD012713-bbs2-0079]This was a case series with fewer than 10 participants[@CD012713-bbs2-0080]This was a case series with fewer than 10 participants[@CD012713-bbs2-0081]This was a single case report[@CD012713-bbs2-0082]This was a single case report[@CD012713-bbs2-0083]This was a single case report[@CD012713-bbs2-0084]This was a case series with fewer than 10 participants[@CD012713-bbs2-0085]This case series reported different outcomes from those in our review[@CD012713-bbs2-0086]This was a cohort study that did not compare ribavirin to supportive care only ‐ no comparator arm[@CD012713-bbs2-0087]This was an overlapping study reporting the same data as an included study ([@CD012713-bbs2-0019])[@CD012713-bbs2-0088]This was a quasi‐RCT that did not report on ribavirin compared to supportive care only ‐ all participants received ribavirin with or without corticosteroids[@CD012713-bbs2-0090]This was a cohort study that did not compare ribavirin to supportive care only ‐ no comparator arm[@CD012713-bbs2-0089]This was a case series with fewer than 10 participants[@CD012713-bbs2-0091]This was a case series with fewer than 10 participants[@CD012713-bbs2-0092]This was a case series with fewer than 10 participants[@CD012713-bbs2-0093]This was a single case report[@CD012713-bbs2-0094]This was a single case report[@CD012713-bbs2-0095]This was a case series with fewer than 10 participants[@CD012713-bbs2-0096]This was a case series with fewer than 10 participants[@CD012713-bbs2-0097]This was a case series with fewer than 10 participants.[@CD012713-bbs2-0098]This was a case series with fewer than 10 participants[@CD012713-bbs2-0099]This was a case series with fewer than 10 participants[@CD012713-bbs2-0100]This was a single case report[@CD012713-bbs2-0101]This was a single case report[@CD012713-bbs2-0102]This was a single case report[@CD012713-bbs2-0103]This was a case series with fewer than 10 participants[@CD012713-bbs2-0104]This was a case series with fewer than 10 participants[@CD012713-bbs2-0105]This was a case series with fewer than 10 participants[@CD012713-bbs2-0106]This did not report on ribavirin use in CCHF[@CD012713-bbs2-0107]This did not report on ribavirin use in CCHF[@CD012713-bbs2-0108]This did not report on ribavirin use in CCHF[@CD012713-bbs2-0109]This was a case series with fewer than 10 participants[@CD012713-bbs2-0110]This did not report on ribavirin use in CCHF[@CD012713-bbs2-0111]This was a case series with fewer than 10 participants[@CD012713-bbs2-0112]This was a survey that did not report on ribavirin use for treatment of CCHF[@CD012713-bbs2-0113]This was a single case report[@CD012713-bbs2-0075]This was a case series with fewer than 10 participants[^6]
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[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: ^1^In addition there were three non‐randomized studies (mixed retrospective and prospective cohort; single arm cohort with historical control; matched case series) with serious risk of bias (ROBINS‐I), providing an estimate of RR 0.59, 95% CI 0.27 to 1.27; 549 participants; very low‐certainty evidence). ^2^Downgraded one level for risk of bias: one RCT with no description of randomisation or concealment of allocation. ^3^Downgraded two levels for imprecision. Few events and wide CI containing appreciable benefit and harm. ^4^In addition one non‐randomized study (matched case series) with serious risk of bias (ROBINS‐I) providing an estimate of 0.8 days fewer in the experimental group (2.7 days fewer to 1.1 days longer); very low‐certainty evidence.

[^3]: ^1^Early defined according to that reported in the included study (\< 4 days since onset of symptoms) ^2^Downgraded one level for risk of bias: all studies at serious risk of bias. ^3^Downgraded two levels for imprecision: few events and wide CIs.

[^4]: Reproduced from [@CD012713-bbs2-0146].

[^5]: Abbreviations: FFP = fresh frozen plasma; h = hours; NR: not reported; PRC: packed red cells; RBV: ribavirin; SAE: serious adverse event; SD: standard deviation

[^6]: RCT: randomized controlled trial
